var title_f0_57_912="Vallecular cyst";
var content_f0_57_912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vallecular cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Congenital vallecular cysts arise in the hypopharynx. They contain respiratory epithelium and mucous glands.",
"    <div class=\"footnotes\">",
"     U: uvula; vc: vallecular cyst.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_57_912=[""].join("\n");
var outline_f0_57_912=null;
var title_f0_57_913="Night splint";
var content_f0_57_913=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Night splint applied to the right foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jill Ferrari, PhD, BSc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_57_913=[""].join("\n");
var outline_f0_57_913=null;
var title_f0_57_914="Patient information: Sore throat in adults (The Basics)";
var content_f0_57_914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?17/55/18291\">",
"         Patient information: Cough, runny nose, and the common cold (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/40/40578\">",
"         Patient information: Fever in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/47/33522\">",
"         Patient information: Flu (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/15/36082\">",
"         Patient information: Sore throat in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/22/3427\">",
"         Patient information: Sore throat in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sore throat in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/sore-throat-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H392020373\">",
"      <span class=\"h1\">",
"       When should I see a doctor or nurse about a sore throat?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people do not need to see a doctor about a sore throat. It usually gets better on its own. But sore throat can sometimes be serious.",
"     </p>",
"     <p>",
"      See a doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have a fever of at least 101&deg;F or 38.4&deg;C",
"       </li>",
"       <li>",
"        Your throat pain is severe or does not start to improve within 5 to 7 days",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Call 9-1-1 or go to the emergency room if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have trouble breathing",
"       </li>",
"       <li>",
"        Are drooling because you cannot swallow your saliva",
"       </li>",
"       <li>",
"        Have swelling of the neck or tongue",
"       </li>",
"       <li>",
"        Cannot move your neck or have trouble opening your mouth",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H392020380\">",
"      <span class=\"h1\">",
"       What causes sore throat?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sore throat is usually caused by an infection. Two types of germs can cause it: viruses and bacteria. People who have a sore throat caused by a virus do not usually need to see a doctor or nurse. People who have a sore throat caused by bacteria might need to see a doctor or nurse. They might have a type of infection called strep throat. Only about 1 in 10 adults who seek medical care for sore throat have strep throat.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H392020387\">",
"      <span class=\"h1\">",
"       How can I tell if my sore throat is caused by a virus or strep throat?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is hard to tell the difference. But there are some clues to look for.",
"     </p>",
"     <p>",
"      People who have a sore throat caused by a virus usually have other symptoms, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A runny nose",
"       </li>",
"       <li>",
"        A stuffed-up chest",
"       </li>",
"       <li>",
"        Itchy or red eyes",
"       </li>",
"       <li>",
"        Cough",
"       </li>",
"       <li>",
"        A raspy (hoarse) voice",
"       </li>",
"       <li>",
"        Pain in the roof of the mouth",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who have a sore throat caused by strep throat DO NOT usually have a cough, runny nose, or itchy or red eyes. But they might have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Severe throat pain",
"       </li>",
"       <li>",
"        Fever (temperature higher than 100.4&deg;F or 38&deg;C)",
"       </li>",
"       <li>",
"        Swollen glands in the neck",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you think you have strep throat, the doctor or nurse can check you for it easily. He or she can run a swab (Q-Tip) along the back of your throat and test it for the bacteria that cause strep throat.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H392020394\">",
"      <span class=\"h1\">",
"       Do I need antibiotics?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have an infection caused by a virus, you DO NOT need antibiotics. But if you have strep throat, you should get antibiotics. Most people with strep throat get better without antibiotics, but doctors and nurses often prescribe them anyway. That's because antibiotics can prevent problems sometimes caused by strep throat. Plus, antibiotics can reduce the symptoms of strep throat and prevent its spread to other people.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H392020401\">",
"      <span class=\"h1\">",
"       What can I do to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want some relief from the pain of sore throat, you can take pain medicine that you can get without a prescription. Throat sprays are no better at soothing pain than sucking on cough drops or candy. Some people feel relief if they gargle with salt water.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H392020408\">",
"      <span class=\"h1\">",
"       When can I go back to work or school?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have strep throat, wait 1 day after starting antibiotics. By then you will be a lot less likely to spread the infection. If you do not have strep throat, you can go back as soon as you feel well.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H392020415\">",
"      <span class=\"h1\">",
"       What can I do to prevent getting a sore throat again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Wash your hands often with soap and water. It is one of the best ways to prevent the spread of infection. You can use an alcohol rub instead, but make sure the hand rub gets everywhere on your hands.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H392020422\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/55/18291?source=see_link\">",
"       Patient information: Cough, runny nose, and the common cold (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=see_link\">",
"       Patient information: Fever in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       Patient information: Flu (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36082?source=see_link\">",
"       Patient information: Sore throat in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/22/3427?source=see_link\">",
"       Patient information: Sore throat in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?0/57/914?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15371 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_57_914=[""].join("\n");
var outline_f0_57_914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H392020373\">",
"      When should I see a doctor or nurse about a sore throat?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H392020380\">",
"      What causes sore throat?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H392020387\">",
"      How can I tell if my sore throat is caused by a virus or strep throat?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H392020394\">",
"      Do I need antibiotics?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H392020401\">",
"      What can I do to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H392020408\">",
"      When can I go back to work or school?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H392020415\">",
"      What can I do to prevent getting a sore throat again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H392020422\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/55/18291?source=related_link\">",
"      Patient information: Cough, runny nose, and the common cold (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36082?source=related_link\">",
"      Patient information: Sore throat in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/22/3427?source=related_link\">",
"      Patient information: Sore throat in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_57_915="Cutaneous schistosomiasis swimmers itch";
var content_f0_57_915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous schistosomiasis (swimmer's itch)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Swimmer's itch consists of erythematous pruritic papules after exposure to water contaminated by cercariae of bird schistosomes carried by intermediate snail hosts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_57_915=[""].join("\n");
var outline_f0_57_915=null;
var title_f0_57_916="Edrophonium and atropine: Patient drug information";
var content_f0_57_916=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Edrophonium and atropine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/27/11700?source=see_link\">",
"     see \"Edrophonium and atropine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2527470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Enlon-Plus&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691229",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Edrophonium is used to help the muscles work again after surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Atropine avoids the side effects of edrophonium, such as a slow heartbeat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to edrophonium, atropine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a latex allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703579",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Glaucoma, bowel block, or trouble passing urine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697142",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a slow heartbeat, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698348",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Slow heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing. Slow breathing, shallow breathing, or trouble breathing are all signs of this. Call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More secretions.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11531 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_57_916=[""].join("\n");
var outline_f0_57_916=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2527470\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029497\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029496\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029500\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029501\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029503\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029499\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029504\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029505\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/27/11700?source=related_link\">",
"      Edrophonium and atropine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_57_917="Histrelin: Pediatric drug information";
var content_f0_57_917=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Histrelin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?18/60/19397?source=see_link\">",
"    see \"Histrelin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/28/11716?source=see_link\">",
"    see \"Histrelin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Supprelin&reg; LA;",
"     </li>",
"     <li>",
"      Vantas&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2934287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vantas&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1017783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gonadotropin Releasing Hormone Agonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1017815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/60/19397?source=see_link\">",
"      see \"Histrelin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children  &ge;2 years:",
"     <b>",
"      Central precocious puberty:",
"     </b>",
"     SubQ: Supprelin&reg; LA: 50 mg implant surgically inserted every 12 months; discontinue at the appropriate time for the onset of puberty",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Prostate cancer, advanced:",
"     </b>",
"     SubQ: Vantas&reg;: 50 mg implant surgically inserted every 12 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Children and Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     : 15-60 mL/minute: No dosage adjustments are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Children and Adults: There are no dosage adjustments provided in manufacturer's labeling; has not been adequately studied.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Implant, subcutaneous:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Supprelin&reg; LA: 50 mg (1s) [releases ~65 mcg/day over 12 months]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vantas&reg;: 50 mg (1s) [Releases ~50 mcg/day over 12 months; packaged with implantation kit]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vantas&reg;: 50 mg (1s [DSC]) [releases 50-60 mcg/day over 12 months]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1017819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Surgical implantation within a sterile field using provided implantation device is required; insert into the inner portion of the upper arm; it is preferable to use the patient's nondominant arm for placement; implant should be placed halfway between the shoulder and the elbow at the crease between the tricep and the bicep. Implant removal should occur after ~12 months; a replacement implant may be inserted if therapy is to be continued. For removal, palpate area of incision to locate implant; if not readily palpated, ultrasound, CT, or MRI may be necessary to locate implant; plain films are not recommended because the implant is not radiopaque.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1017801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Supprelin&reg; LA, Vantas&reg;: Store implant  at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); excursions permitted to 25&deg;C (77&deg;F) for 7 days; if unused within the 7 days, may return to proper refrigeration until product expiration date. Keep implant wrapped in the amber pouch for protection from light; do not freeze. The insertion kit does not require refrigeration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1017784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Supprelin&reg; LA:  Treatment of children with either neurogenic or idiopathic central precocious puberty (CPP) (FDA approved in ages &ge;2 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vantas&reg;: Palliative treatment of advanced prostate cancer (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F179214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CPP:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Metrorrhagia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Insertion site reaction (includes bruising, discomfort, itching, pain, protrusion of implant area, soreness, swelling, tingling); keloid scar, pain at the application site, post procedural pain, scar, suture-related complication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Amblyopia, breast tenderness, cold feeling, disease progression, dysmenorrhea, epistaxis, erythema, flu-like syndrome, gynecomastia, headache, infection at the implant site, menorrhagia, migraine, mood swings, pituitary adenoma, pituitary apoplexy, pruritus, seizures, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Prostate cancer:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia, hot flashes, libido decreased, sexual dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Testicular atrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Implant site reaction (includes bruising, erythema, pain, soreness, swelling, tenderness)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal discomfort, alopecia, anemia, appetite increased, arthralgia, AST increased, back pain, bone density decreased, bone pain, breast pain, breast tenderness, cold feeling, contusion, craving food, creatinine increased, depression, diaphoresis, dizziness, dyspnea (exertional), dysuria, fluid retention, flushing, genital pruritus, hematoma, hematuria, hepatic injury (severe), hypercalcemia, hypercholesterolemia, hyperglycemia, irritability, LDH increased, lethargy, limb pain, liver disorder, malaise, muscle twitching, myalgia, nausea, neck pain, night sweats, pain, palpitation, peripheral edema, prostatic acid phosphatase increased, pruritus, pituitary apoplexy, renal calculi, renal failure, stent occlusion, testosterone increased, tremor, urinary frequency, urinary retention, ventricular asystoles, weakness, weight loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1017788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to histrelin acetate, GnRH, GnRH-agonist analogs, or any component; females who are or may become pregnant",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F15848559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment; safety and efficacy have not been established in prostate cancer patients with hepatic dysfunction. Use with caution in patients with cardiovascular disease; androgen deprivation therapy may increase the risk for cardiovascular disease (Levine, 2010); an increased risk of MI, sudden cardiac death, and stroke has been reported with GnRH agonist use in men; monitor for symptoms associated with cardiovascular disease. Insertion of subcutaneous implant is a surgical procedure requiring aseptic conditions and proper technique to minimize complications and possible implant expulsion; spontaneous extrusion of the implant has been reported rarely.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1017789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When used for treatment of central precious puberty, initial agonistic action of histrelin may cause transient increases in estradiol serum levels (female) or testosterone levels (female and male); typically during first week of therapy;  worsening of symptoms or onset of new symptoms may occur during this time; however, manifestations of puberty should decrease within 4 weeks. Rare cases of pituitary apoplexy have been observed, frequently secondary to pituitary adenoma; reported onset from 1 hour to usually &lt;2 weeks; may present as sudden headache, vomiting, visual or mental status changes, and infrequently cardiovascular collapse; immediate medical attention required if occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Transient increases in serum testosterone (in men with prostate cancer) occur during the first week of use and may result in a worsening of disease signs and symptoms (bone pain, neuropathy, hematuria, ureteral/bladder outlet obstruction, spinal cord compression) during the first week of treatment; closely observe patients for urinary tract obstruction or poor urine output in first few weeks of therapy. Spinal cord compression has been reported and may contribute to paralysis when used for prostate cancer; closely observe patients with metastatic vertebral lesions for weakness and paresthesias in first few weeks of therapy. Hyperglycemia has been reported with androgen deprivation therapy (in prostate cancer) and may manifest as diabetes or worsening of pre-existing diabetes. Monitor blood glucose and/or Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F179166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F179169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F179180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal harm and an increase in fetal mortalities have been noted in animal studies. Histrelin is contraindicated for use during pregnancy or in women who may become pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1017821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central precocious puberty:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Manufacturer labeling: LH, FSH, estradiol, or testosterone serum concentration (after 1 month then every 6 months); height, bone age (every 6-12 months); Tanner staging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Consensus recommendation: Tanner stage and growth (growth velocity, height) every 3-6 months and bone age periodically. Routine or random stimulated measurements of gonadotropins or sex steroids may be used, particularly if suboptimal response; however, use of FSH levels not typically used (Carel, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostate cancer: Serum testosterone levels, prostate specific antigen (PSA); bone mineral density; weakness, paresthesias, and urinary tract obstruction (especially during first few weeks of therapy); screen for diabetes; monitor for symptoms associated with cardiovascular disease",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1017803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent inhibitor of gonadotropin secretion; after an initiation phase, continuous administration results in the suppression of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and a subsequent decrease in testosterone and dihydrotestosterone (males) and estrone and estradiol (premenopausal females). Testosterone levels are reduced to castrate levels in males (treated for prostate cancer) within 2-4 weeks. Additionally, in patients with CPP, linear growth velocity is slowed (improves chance of attaining predicted adult height).",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F15848560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CPP: Within 1 month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prostate cancer:  Within 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 1 year",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1017806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~58 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 70% &plusmn; 9%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via C-terminal dealkylation and hydrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 92%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1017824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/28/11716?source=see_link\">",
"      see \"Histrelin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Follow directions for care of insertion site. Wait 24 hours before allowing moisture or water to touch the arm and 7 days before participating in strenuous activity or heavy lifting. Report immediately any redness, swelling, pain, drainage, or tingling at insertion site. Increased or worsened symptoms (eg, increased bone pain) may occur during first week following insertion and should subside. May cause hot flashes; dizziness, headache, insomnia, or irritability; enlarged or painful breasts, decreased libido, or sexual dysfunction; constipation; weight gain; or loss of hair. Report any persistent difficulty urinating; shortness of breath; chest pain or cardiac abnormalities; muscle pain, twitching, or weakness; or persistent dizziness, confusion, depression, or mood swings.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Carel JC, Eugster EA, Rogol A, et al, \"Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 752-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/57/917/abstract-text/19332438/pubmed\" id=\"19332438\" target=\"_blank\">",
"        19332438",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eugster EA, Clarke W, Kletter GB, et al, \"Efficacy and Safety of Histrelin Subdermal Implant in Children With Central Precocious Puberty: A Multicenter Trial,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2007, 92(5):1697-704.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/57/917/abstract-text/17327379/pubmed\" id=\"17327379\" target=\"_blank\">",
"        17327379",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, D&rsquo;Amico AV, Berger P, et al, &ldquo;Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 121:831-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/57/917/abstract-text/20124128/pubmed\" id=\"20124128\" target=\"_blank\">",
"        20124128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rahhal S, Clarke WL, Kletter GB, et al, \"Results of a Second Year of Therapy With the 12-Month Histrelin Implant for the Treatment of Central Precocious Puberty,\"",
"      <i>",
"       Int J Pediatr Endocrinol",
"      </i>",
"      , 2009, 2009:812517.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/57/917/abstract-text/19956699/pubmed\" id=\"19956699\" target=\"_blank\">",
"        19956699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87619 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-2ED5F37753-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_57_917=[""].join("\n");
var outline_f0_57_917=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179193\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934287\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017783\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017815\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179173\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179161\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017819\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017801\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017784\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179214\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017788\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15848559\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017789\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299447\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179166\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179169\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179180\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017821\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017803\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15848560\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017806\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017824\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87619\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87619|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/60/19397?source=related_link\">",
"      Histrelin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/28/11716?source=related_link\">",
"      Histrelin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_57_918="Denileukin diftitox: Drug information";
var content_f0_57_918=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Denileukin diftitox: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/31/27124?source=see_link\">",
"    see \"Denileukin diftitox: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ONTAK&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F157529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F157514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate with an antihistamine and acetaminophen prior to each infusion; corticosteroid premedication (eg, dexamethasone) may reduce the incidence of hypersensitivity and edema (Foss, 2001). Withhold treatment if serum albumin &lt;3 g/dL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cutaneous T-cell lymphoma (CTCL), persistent/recurrent:",
"     </b>",
"     I.V.: 9 or 18 mcg/kg once daily on days 1 through 5 every 21 days for 8 cycles (Olsen, 2001; Prince, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Peripheral T-cell lymphoma (PTCL), relapsed/refractory (unlabeled use):",
"     </b>",
"     I.V.: 18 mcg/kg once daily for 5 consecutive days every 21 days for up to 8 cycles (Dang, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F157515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15513493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15513494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F6780343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum albumin &lt;3 g/dL: Withhold treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe infusion reaction: Permanently discontinue treatment",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F157494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ONTAK&reg;: 150 mcg/mL (2 mL) [contains edetate disodium]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F157480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F157497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.V. use only. Infuse over 30-60 minutes. Should",
"     <b>",
"      not",
"     </b>",
"     be given as a rapid I.V. bolus. Discontinue or reduce infusion rate for infusion related reactions; discontinue for severe infusion reaction. Do not administer through an in-line filter. Premedicate with an antihistamine and acetaminophen; consider corticosteroid premedication.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F157495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6780245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F157527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Capillary leak syndrome (33%; serious: 11%), peripheral edema (20% to 26%), vasodilation (22%), hypotension (7% to 16%), chest pain (4% to 13%), tachycardia (12%), thrombosis-related events (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (49% to 64%), fatigue (44% to 47%), headache (26% to 29%), dizziness (11% to 13%), pain (11% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (20% to 24%), pruritus (16% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoalbuminemia (14% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (47% to 60%), vomiting (13% to 35%), diarrhea (22%), anorexia (9% to 20%), taste disturbance (11% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Lymphopenia (70%; 24% had lymphopenia at baseline)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (84%), AST increased (84%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Rigors (42% to 47%), myalgia (18% to 20%), weakness (18%), back pain (16% to 18%), arthralgia (13% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (18% to 20%), upper respiratory infection (13%), dyspnea (11% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Antibody formation (76% to 100%) neutralizing antibodies (45% to 97%), flu-like syndrome (&le;85%), infusion reaction (71%; serious: 8%), infection (48%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia (6%), hypertension (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (grades 3/4: 3% to 6%), neutropenia (grades 3/4: 3%), thrombocytopenia (grades 3/4: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual changes (serious: 4%; includes loss of visual acuity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (3% to 10%), proteinuria/casts/hematuria (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Acute renal insufficiency, hyper-/hypothyroidism, oral ulcer, pancreatitis, thyroiditis, thyrotoxicosis, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F157500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F157484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Capillary leak syndrome:",
"     <b>",
"      [U.S. Boxed Warning]: Has been associated with a potentially severe, including life-threatening, capillary leak syndrome (CLS); monitor weight, edema, blood pressure, and serum albumin prior to and during treatment.",
"     </b>",
"     Symptoms of capillary leak syndrome (defined as occurrence of &ge;2 of the following symptoms: hypotension, edema, hypoalbuminemia) may be delayed, occurring up to 2 weeks postinfusion; symptoms may persist or worsen after treatment cessation. Withhold treatment if serum albumin &lt;3 g/dL; pre-existing low serum albumin levels may correlate with capillary leak syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Serious and fatal infusion reactions have occurred. Administer in a facility appropriate for cardiopulmonary resuscitation.  Discontinue immediately and permanently with serious infusion reaction.",
"     </b>",
"     Infusion reaction symptoms usually occur within 24 hours of infusion and resolve within 48 hours of last infusion of cycle. Incidence of infusion reaction has been reported to be lower in cycles 3 and 4 (compared to cycles 1 and 2). The manufacturer recommends premedication with an antihistamine and acetaminophen; corticosteroid (eg, dexamethasone) premedication may help to reduce the incidence of hypersensitivity and edema (Foss, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunogenicity: May develop immunogenicity; patients with antibodies have a two- to threefold increase in clearance. The presence of antibodies does not correlate with risk for hypersensitivity/infusion related reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Monitor closely for infection; may impair immune function; patients with CTCL are predisposed to cutaneous infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vision loss:",
"     <b>",
"      [U.S. Boxed Warning]: Loss of visual acuity, usually associated with loss of color vision (with or without retinal pigment mottling) has been reported.",
"     </b>",
"     Most patients have persistent visual impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients &gt;65 years of age; adverse events (anemia, anorexia, confusion, hypotension, rash, nausea/vomiting) may occur more frequently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Confirm CD25 expression on malignant cells prior to treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Denileukin Diftitox may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F157503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Should be given to a pregnant woman only if clearly needed",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F157521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F157504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The excretion of denileukin diftitox in breast milk is unknown; however, due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue denileukin diftitiox or to discontinue breast-feeding should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ontak Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mcg/mL (2 mL): $1863.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F157492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline CD25 expression (on malignant cells); serum albumin level (prior to each treatment), CBC, blood chemistry panel, renal and hepatic function tests (prior to initiation of therapy and weekly during therapy). During the infusion, the patient should be monitored for symptoms of an infusion reaction. After infusion, the patient should be monitored for the development of a delayed capillary leak syndrome (usually in the first 2 weeks), including careful monitoring of weight, edema (new or worsening), blood pressure, and serum albumin.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Thyroid function monitoring (Hamnvik, 2011): TSH and anti-TPO antibodies at baseline; then monitor TSH every month for 3 months, then every 2-3 months",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Information on assay for malignant cell CD25 expression is available at 1-877-873-4724.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F157483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Denileukin diftitox is a fusion protein (a combination of amino acid sequences from diphtheria toxin and interleukin-2) which selectively delivers the cytotoxic activity of diphtheria toxin to targeted cells. It interacts with the high-affinity IL-2 receptor on the surface of malignant cells to inhibit intracellular protein synthesis, rapidly leading to cell death.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F157499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.06-0.09 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via proteolytic degradation (animal studies)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Distribution: 2-5 minutes; Terminal: 70-80 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dang NH, Pro B, Hagemeister FB, et al, &ldquo;Phase II Trial of Denileukin Diftitox for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2007, 136(3):439-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/57/918/abstract-text/17233846/pubmed\" id=\"17233846\" target=\"_blank\">",
"        17233846",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foss FM, Bacha P, Osann KE, et al, &ldquo;Biological Correlates of Acute Hypersensitivity Events With DAB389IL-2 (Denileukin Diftitox, Ontak&reg;) in Cutaneous T-Cell Lymphoma: Decreased Frequency and Severity With Steroid Premedication,&rdquo;",
"      <i>",
"       Clin Lymphoma",
"      </i>",
"      , 2001, 1(4):298-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/57/918/abstract-text/11707845/pubmed\" id=\"11707845\" target=\"_blank\">",
"        11707845",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foss F, Demierre MF, and DiVenuti F, &ldquo;A Phase-1 Trial of Bexarotene and Denileukin Diftitox in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2005, 106(2):454-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/57/918/abstract-text/15811959/pubmed\" id=\"15811959\" target=\"_blank\">",
"        15811959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frankel AE, Surendranathan A, Black JH, et al, &ldquo;Phase II Clinical Studies of Denileukin Diftitox Diphtheria Toxin Fusion Protein in Patients With Previously Treated Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 106(10):2158-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/57/918/abstract-text/16586495/pubmed\" id=\"16586495\" target=\"_blank\">",
"        16586495",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2011, 103(21):1572-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/57/918/abstract-text/22010182/pubmed\" id=\"22010182\" target=\"_blank\">",
"        22010182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuzel TM, Li S, Eklund J, et al, &ldquo;Phase II Study of Denileukin Diftitox for Previously Treated Indolent Non-Hodgkin Lymphoma: Final Results of E1497,&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 2007 48(12):2397-402.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/57/918/abstract-text/17943599/pubmed\" id=\"17943599\" target=\"_blank\">",
"        17943599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olsen E, Duvic M, Frankel A, et al, &ldquo;Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(2):376-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/57/918/abstract-text/11208829/pubmed\" id=\"11208829\" target=\"_blank\">",
"        11208829",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Polder K, Wang C, Duvic M, et al, &ldquo;Toxic Epidermal Necrolysis Associated With Denileukin Diftitox (DAB",
"      <sub>",
"       389",
"      </sub>",
"      IL-2) Administration in a Patient With Follicular Large Cell Lymphoma,&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 2005, 46(12):1807-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/57/918/abstract-text/16263585/pubmed\" id=\"16263585\" target=\"_blank\">",
"        16263585",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prince HM, Duvic M, Martin A, et al, &ldquo;Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(11):1870-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/57/918/abstract-text/20212249/pubmed\" id=\"20212249\" target=\"_blank\">",
"        20212249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Talpur R, Apisarnthanarax N, Ward S, et al, &ldquo;Treatment of Refractory Peripheral T-Cell Lymphoma With Denileukin Diftitox (Ontak&reg;),&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 2002, 43(1):121-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/57/918/abstract-text/11908715/pubmed\" id=\"11908715\" target=\"_blank\">",
"        11908715",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8624 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-0E8DCFA2F5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_57_918=[""].join("\n");
var outline_f0_57_918=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708696\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157513\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157529\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157514\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157515\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513493\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513494\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6780343\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157494\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157480\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157497\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157495\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6780245\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401604\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157527\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157500\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157484\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299133\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219706\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157503\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157521\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157504\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323097\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157492\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157483\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157499\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8624\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8624|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/31/27124?source=related_link\">",
"      Denileukin diftitox: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_57_919="Tracheomalacia CXR";
var content_f0_57_919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65009%7EPULM%2F74889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65009%7EPULM%2F74889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tracheomalacia following longterm intubation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is a well-positioned tracheostomy tube. Note that the tracheal air column is abnormally distended by the tracheostomy cuff (red arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomographic scans of the chest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 524px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper image shows an endotracheal tube (ETT) at the level of the mid-trachea; the wide ring of air surrounding teh tube suggests ETT cuff over-inflation, a risk factor for iatrogenic tracheal injury. The lower image demonstrates a focal injury to the posterior tracheal wall and herniation of the cuff into the posterior mediastinum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_57_919=[""].join("\n");
var outline_f0_57_919=null;
var title_f0_57_920="Palmoplantar pustulosis - heel";
var content_f0_57_920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62582%7EDERM%2F82843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62582%7EDERM%2F82843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palmoplantar pustulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pustules are present within an erythematous, scaly plaque.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Palmoplantar pustulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_57_920=[""].join("\n");
var outline_f0_57_920=null;
var title_f0_57_921="Benign partial epilepsies of childhood";
var content_f0_57_921=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Benign partial epilepsies of childhood",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/57/921/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/57/921/contributors\">",
"     Selim R Benbadis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/57/921/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/57/921/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/57/921/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/57/921/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/57/921/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign partial epilepsies of childhood are idiopathic syndromes that occur in developmentally and neurologically normal children and have a benign course, remitting prior to adulthood. These idiopathic epilepsies are distinguished from symptomatic partial epilepsy, which refers to epilepsy that results from brain injury or other structural brain disease. Thus, the benign partial epilepsies of childhood can be viewed as a spectrum of conditions with \"functional\" or \"non-lesional\" focal epileptogenicity, each characterized by a location and seizure type(s). This is sometimes referred to as the benign childhood susceptibility syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best-described syndromes are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Benign (childhood) epilepsy with centrotemporal spikes (BCECTS or BECTS) or benign rolandic epilepsy",
"     </li>",
"     <li>",
"      Benign occipital epilepsy of childhood (Gastaut syndrome)",
"     </li>",
"     <li>",
"      Panayiotopoulos syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These disorders will be reviewed here. Symptomatic partial (localization-related) epilepsies and other epileptic syndromes in childhood are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link\">",
"     \"Epilepsy syndromes in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BENIGN EPILEPSY WITH CENTROTEMPORAL SPIKES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign (childhood) epilepsy with centrotemporal spikes (BECTS or BCECTS), also known as benign rolandic epilepsy, makes up about 10 to 20 percent of all childhood epilepsies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Age of onset is between 3 and 13 years, with a peak incidence between 7 and 9 years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presumed genetic basis of BECTS remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/8\">",
"     8",
"    </a>",
"    ]. Although more than one-fourth of patients have a family history of epilepsy, usually a focal epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], a lack of concordance among twin pairs argues against a major role for Mendelian-inherited factors in the development of BECTS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, the hallmark electroencephalographic (EEG) finding of centrotemporal spikes does appear to be inherited as an autosomal dominant trait [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In some families with this EEG trait, a linkage was found on chromosome 15q14 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. Another study identified different mutations in the potassium channel gene KCNQ2 in some families with BECTS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common seizure type is a simple partial seizure with motor symptoms involving the face [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/7,15,16\">",
"     7,15,16",
"    </a>",
"    ]. The characteristic ictal symptoms correspond to the origin of seizures in the rolandic or perisylvian sensorimotor cortex, which represents the face and oropharynx, and include facial numbness or twitching, guttural vocalizations, hypersalivation, drooling, dysphasia, and speech arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. Motor activity in the upper but not lower extremity is also common. Three-quarters of seizures occur at night or on awakening [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/7,15,16\">",
"     7,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these focal seizures are the most frequent seizure type, they can go unnoticed, especially because they occur mainly in sleep. As a result, a common presentation of BECTS is a secondary generalized tonic clonic (GTC) seizure during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/3,16\">",
"     3,16",
"    </a>",
"    ]. Overall, about half of children with BECTS have at least one secondary generalized seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. Partial or generalized status epilepticus is unusual [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A distinct clinical subset of patients with BECTS has been described in seven patients who had typical EEG findings, but predominantly atonic seizures that occurred several times a day and began at a somewhat earlier age (mean 2.4 years) than children with more typical BECTS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several small studies suggest that children with BECTS can have mild cognitive deficits and behavioral problems such as attention deficit disorder and dyslexia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/23-35\">",
"     23-35",
"    </a>",
"    ]. As an example, neuropsychological testing in 42 children with BECTS revealed overall normal intelligence and language ability with a specific pattern of deficits in memory and phonologic awareness, disproportionate to other abilities [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/25\">",
"     25",
"    </a>",
"    ]. Another study found that 13 patients, along with 11 epilepsy-free siblings, had mild but similar deficits in language and attention [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/35\">",
"     35",
"    </a>",
"    ]. These findings should be interpreted with caution, as the study groups were small, and antiepileptic drugs could have affected the neuropsychological test results. In addition, cognitive function can be transiently abnormal following a seizure, the time of the child's last seizure was not reported, and the investigators' interest in cognitive function in children with epilepsy likely introduced a referral bias. Another possible contributor to cognitive impairments are sleep disturbances which, in one study, occurred in a higher number of children with BECTS than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Electroencephalography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electroencephalogram (EEG) findings of BECTS are characteristic, with centrotemporal sharp waves (70 to 100 msec) that have several distinctive features (",
"    <a class=\"graphic graphic_waveform graphicRef75634 \" href=\"UTD.htm?24/3/24634\">",
"     waveform 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/3,4,15,37\">",
"     3,4,15,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The morphology is biphasic, with a negative sharp peak followed by a positive rounded component (amplitude 50 percent of the negativity)",
"     </li>",
"     <li>",
"      The sharp waves often have a \"horizontal dipole,\" which typically reveals a maximum negativity in the centrotemporal region and a maximum positivity at the vertex or in the frontal region",
"     </li>",
"     <li>",
"      The sharp waves often occur in repetitive bursts, and can be bilateral and independent",
"     </li>",
"     <li>",
"      Epileptiform activity is markedly activated by non-REM sleep, and occasionally occurs only in sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/3,15,38\">",
"       3,15,38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The background EEG activity is normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although this distinctive EEG appearance is highly associated with BECTS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/39\">",
"     39",
"    </a>",
"    ], these interictal centrotemporal spikes also occur in 1 to 2 percent of asymptomatic children without seizures as well as in other epilepsy syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests, including neurologic examination, neuropsychiatric examination, and imaging studies, are normal in BECTS. Thus, if the history and EEG findings are all consistent with this syndrome, further studies may not be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/16,40\">",
"     16,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atypical features that may indicate further testing (magnetic resonance imaging) to rule out symptomatic partial epilepsy include [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/7,41\">",
"     7,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolonged or frequent seizures or status epilepticus",
"     </li>",
"     <li>",
"      Atypical seizure type",
"     </li>",
"     <li>",
"      Seizures only while awake",
"     </li>",
"     <li>",
"      Atypical EEG features",
"     </li>",
"     <li>",
"      Postictal paresis",
"     </li>",
"     <li>",
"      Older age of onset",
"     </li>",
"     <li>",
"      Abnormal neurologic examination",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, any one of these findings does not exclude BECTS, as they have been reported in individuals who otherwise have clinical features and course that is consistent with BECTS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. In some cases, abnormal neuroimaging findings are coincidental and not related to BECTS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of BECTS is benign. Treated or not, this syndrome has an excellent prognosis, with spontaneous remission in the majority of patients before age 12 to 13 years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/7,46,47\">",
"     7,46,47",
"    </a>",
"    ]. In a case series of 87 patients, the mean duration of epilepsy was two years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The syndrome of BECTS is also benign in other ways. Seizures are typically infrequent, nocturnal, and there is a very low incidence of status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/4,34\">",
"     4,34",
"    </a>",
"    ]. In a meta-analysis of 794 reported cases, 16 percent had only one seizure, and only 5 percent had 15 or more [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/7\">",
"     7",
"    </a>",
"    ]. More frequent seizures and a longer duration of epilepsy appear to occur in those whose onset is prior to 3 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/4,47\">",
"     4,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some children who go on to develop Landau-Kleffner syndrome or other epileptic encephalopathy (eg, epilepsy with continuous spike-waves during slow-wave sleep, atypical benign focal epilepsy of childhood) may have a presentation in early childhood that is typical for BECTS. In reported cases, the more severe diagnosis was apparent within 6 to 24 months after presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/34,48\">",
"     34,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link&amp;anchor=H10#H10\">",
"     \"Epilepsy syndromes in children\", section on 'Landau-Kleffner syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As discussed above, there is some evidence that BECTS may be associated with mild cognitive impairment, particularly with respect to language. Most longitudinal follow-up studies suggest that these cognitive impairments may resolve, with seizures, by adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], however, at least one study found that there was evidence of enduring language deficits into early adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/49\">",
"     49",
"    </a>",
"    ]. In this study as well as others, there was evidence of atypical cortical lateralization of language [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/31,49-51\">",
"     31,49-51",
"    </a>",
"    ]. One case series found that, compared with controls, children with BECTS had significantly hypertrophied putamens, which appeared to be cognitively adaptive, as this finding was associated with improved cognitive performance [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiepileptic drug (AED) treatment is often not recommended, particularly if only simple partial seizures occur and if the child and family are comfortable with this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/7,46\">",
"     7,46",
"    </a>",
"    ]. In an observational case series, almost half of 79 patients were not treated [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/46\">",
"     46",
"    </a>",
"    ]. Treatment was associated with a reduction in generalized but not partial seizures.",
"   </p>",
"   <p>",
"    If treatment is elected because of greater seizure frequency (especially in the daytime) or severity, then moderate doses of a single AED are usually sufficient. Options include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    and other AEDs with demonstrated effectiveness in partial epilepsies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/20,53-57\">",
"     20,53-57",
"    </a>",
"    ]. Sulthiame (not available in the United States) and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/23/35191?source=see_link\">",
"     gabapentin",
"    </a>",
"    have demonstrated efficacy in small placebo-controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\", section on 'Choice of drug'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, AEDs appear to aggravate BECTS, causing increased seizures, worsened EEG appearance, and even neuropsychological abnormalities, all of which clear with discontinuation of the medication [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. This complication has been reported with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/34/3626?source=see_link\">",
"     lamotrigine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    As in most epilepsies, an attempt at weaning AEDs is warranted after a certain period of seizure freedom. One study suggested that a one-year seizure-free duration is sufficient before weaning treatment in patients with BECTS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/62\">",
"     62",
"    </a>",
"    ]. An initial trial of weaning is associated with relapse in approximately 14 percent of patients, but there is little information regarding any factors that might be associated with seizure relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/7\">",
"     7",
"    </a>",
"    ]. Nonetheless, patients and families should be aware of this possibility and participate in the decision to wean off treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     BENIGN CHILDHOOD EPILEPSY WITH OCCIPITAL SPIKES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign childhood epilepsy with occipital spikes has two major variants: Panayiotopoulos syndrome and benign occipital epilepsy of childhood (Gastaut syndrome). However, one case series of 16 patients found that the syndromes were not discrete, with one-third of children showing mixed features of both syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/63\">",
"     63",
"    </a>",
"    ]. Twin pairs in this case series were as likely to be discordant as concordant for benign occipital epilepsy, Panayiotopoulos, or mixed syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Panayiotopoulos syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A syndrome occurring in early childhood, the Panayiotopoulos syndrome presents at a mean age of younger than 5 years (range 1 to 14 years) with a unique seizure type that has prominent autonomic features [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/64-74\">",
"     64-74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Clinical symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The seizures in this syndrome have a distinctive, yet variable phenomenology, compared to other partial epilepsy syndromes. Vomiting is the most characteristic and frequent ictal sign, occurring in 70 to 85 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/64-68,73-75\">",
"     64-68,73-75",
"    </a>",
"    ]. Syncope-like seizures, with sudden loss of muscle tone and unresponsiveness with or without associated autonomic signs, have been described in up to half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/76\">",
"     76",
"    </a>",
"    ]. Other common autonomic signs are pallor, miosis, incontinence, coughing, and hypersalivation. Cardiac disturbances are usually limited to tachycardia, but cardiopulmonary arrest has been described. Visual symptoms, usually as a seizure aura, are variably present. Many seizures are characterized by progressive impairment of consciousness along with staring or head and eye deviation. In some seizures, partial or secondarily generalized clonic activity occurs.",
"   </p>",
"   <p>",
"    The seizures are usually nocturnal and last more than five minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/64-68,74\">",
"     64-68,74",
"    </a>",
"    ]. One-third to one-half of episodes last more than 30 minutes, representing a nonconvulsive (complex partial) status epilepticus. Generalized convulsive status epilepticus is uncommon.",
"   </p>",
"   <p>",
"    A small number of patients (10 to 13 percent) with Panayiotopoulos syndrome also have or develop BECTS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/64,71\">",
"     64,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormalities of visual and visuoperceptual function are uncommon in children with the Panayiotopoulos syndrome, but have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Electroencephalography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interictal EEG shows occipital spikes in approximately 75 percent of cases; however, epileptiform activity arising from other or even multiple areas is not uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/66,70,73,74,78\">",
"     66,70,73,74,78",
"    </a>",
"    ]. The morphology of the spikes is similar to that of benign rolandic epilepsy. As with BECTS described above, the frequency of epileptiform activity increases during sleep, and background activity is normal.",
"   </p>",
"   <p>",
"    Ictal recordings have demonstrated variable loci of seizure onset, including frontal, frontotemporal, and occipital origins [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. The seizure discharge consists mainly of rhythmic theta or delta activity, intermixed with small spikes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Panayiotopoulos syndrome is made in the setting of a suggestive clinical history in a child of the typical age with the characteristic EEG findings. A sleep recording may be required if the routine EEG is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/71\">",
"     71",
"    </a>",
"    ]. Magnetic resonance imaging is normal in Panayiotopoulos syndrome and is not required if the other findings are diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The unusual symptomatology of Panayiotopoulos syndrome requires a high level of suspicion for epilepsy. Because of the prominent dysautonomic features, these seizures can be mistaken for nonepileptic syndromes including syncope, gastroenteritis, encephalitis, and migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/65,71,73,79,80\">",
"     65,71,73,79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Panayiotopoulos syndrome can usually be distinguished from symptomatic temporal lobe epilepsy (TLE). In TLE, autonomic symptoms are usually much less pronounced and occur near the end rather than at the beginning of the seizure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Prognosis and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of Panayiotopoulos syndrome is usually benign. Seizures are infrequent and almost half of patients have just a single seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/65,67,73,74\">",
"     65,67,73,74",
"    </a>",
"    ]. Spontaneous remission usually occurs within two to three years from onset. A few children develop drug-resistant seizures or neuropsychologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/67,70\">",
"     67,70",
"    </a>",
"    ]. Pre-exisiting neurobehavioral disorders may be a risk factor for recurrent, more difficult to treat seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prolonged seizures should be treated as nonconvulsive status epilepticus. Benzodiazepines are generally advocated as the initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/64,65,71\">",
"     64,65,71",
"    </a>",
"    ]. However, there is no evidence that these prolonged seizures pose a risk of brain damage, and experts suggest avoiding \"over-treatment\" with multiple intravenous drugs that have the potential for cardiorespiratory complications [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=see_link\">",
"     \"Management of status epilepticus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylactic treatment is reserved for patients with frequent seizures or those with severe symptoms. Although any of the antiepileptic drugs used for partial epilepsy may be used, there is the most experience with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , which is successful as monotherapy in most patients (88 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/67\">",
"     67",
"    </a>",
"    ]. Withdrawal of treatment is recommended within one to two years if seizures are not ongoing.",
"   </p>",
"   <p>",
"    Rectal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    and instruction in its use should be provided to parents of children who have had a prolonged seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/64,65,71\">",
"     64,65,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Benign occipital epilepsy of childhood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign occipital epilepsy of childhood, sometimes referred to as Gastaut-type, has a mean age of presentation of 8 to 9 years (range 3 to 16 years), which is somewhat later than in Panayiotopoulos syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/71,82\">",
"     71,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizures often include visual symptoms, either blindness or visual hallucinations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/69,73,82-87\">",
"     69,73,82-87",
"    </a>",
"    ]. Hemiclonic activity, automatisms, migraine-like headache, and versive movements can occur, and seizures may secondarily generalize. Compared with Panayiotopoulos syndrome, seizures are more frequent and of shorter duration, usually less than five minutes. Most seizures occur in the daytime.",
"   </p>",
"   <p>",
"    The interictal EEG is similar to that in Panayiotopoulos syndrome, but with some differences: epileptiform activity is more predominantly occipital, often occurs in long bursts of spike-wave complexes, and is markedly activated by eye closure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/55,83,87\">",
"     55,83,87",
"    </a>",
"    ]. Background activity is normal.",
"   </p>",
"   <p>",
"    Because clinical and EEG features of symptomatic and benign idiopathic occipital epilepsy overlap substantially, magnetic resonance imaging is generally recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/40,69,87,88\">",
"     40,69,87,88",
"    </a>",
"    ]. Migraine with aura is also frequently considered in the differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link&amp;anchor=H13#H13\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\", section on 'Occipital lobe epilepsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The course of benign occipital epilepsy of childhood is less consistently benign than the previously described syndromes. Antiepileptic drug treatment is more often prescribed since the duration of epilepsy is longer and seizures can be frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/82,87\">",
"     82,87",
"    </a>",
"    ]. Any medication used in partial epilepsies is likely to be efficacious. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\", section on 'Choice of drug'",
"    </a>",
"    .)",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"     Carbamazepine",
"    </a>",
"    appears to be most commonly prescribed in published cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/86\">",
"     86",
"    </a>",
"    ]. An open-label study suggested that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/0/25608?source=see_link\">",
"     levetiracetam",
"    </a>",
"    may be efficacious as well [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/89\">",
"     89",
"    </a>",
"    ]. Seizures may persist into adulthood, but remit beforehand in two-thirds of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/55,87,90\">",
"     55,87,90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     BENIGN PARTIAL EPILEPSIES IN INFANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of benign partial epilepsy syndromes, both familial and sporadic, have been described in infancy.",
"   </p>",
"   <p>",
"    Benign partial epilepsy in infancy is thought to occur in two distinct forms: one with complex partial seizures and another with secondarily generalized seizures beginning between 3 and 10 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/921/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Half of patients have a family history of infantile seizures.",
"   </p>",
"   <p>",
"    The interictal EEG is normal. The ictal EEG shows rhythmic focal discharges that are predominantly temporal in the complex partial seizure variant and central in those with the secondary generalized seizure variant.",
"   </p>",
"   <p>",
"    Seizures remit in more than 90 percent of patients within four months and in all patients within two years. Neurologic development is normal.",
"   </p>",
"   <p>",
"    Other benign partial epilepsies occurring in infancy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Benign infantile convulsions (familial and sporadic forms) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35783?source=see_link&amp;anchor=H9#H9\">",
"       \"Neonatal epileptic syndromes\", section on 'Benign familial neonatal convulsions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35783?source=see_link&amp;anchor=H5#H5\">",
"       \"Neonatal epileptic syndromes\", section on 'Benign neonatal convulsions'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Benign infantile familial convulsions and choreoathetosis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link&amp;anchor=H3#H3\">",
"       \"Epilepsy syndromes in children\", section on 'Seizure syndromes with onset in the first year of life'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Benign infantile convulsions associated with mild gastroenteritis",
"     </li>",
"     <li>",
"      Benign infantile focal epilepsy with midline spikes and waves during sleep",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/54/38754?source=see_link\">",
"       \"Patient information: Epilepsy in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/26/419?source=see_link\">",
"       \"Patient information: Seizures in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/5/19540?source=see_link\">",
"       \"Patient information: Treatment of seizures in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign partial epilepsies of childhood share as common features a normal neurologic and developmental history, age-dependent onset, specific clinical and electroencephalographic features, and a favorable long-term prognosis with spontaneous seizure remission prior to adulthood.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign (childhood) epilepsy with centrotemporal spikes (BECTS, also called benign rolandic epilepsy) is the most common, presenting at a mean age of 8 years, with partial motor or secondarily generalized seizures that occur mostly at night. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Benign epilepsy with centrotemporal spikes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Centrotemporal spikes are seen on EEG in patients with BECTS. These have a distinctive morphology and are increased with sleep. Although this EEG pattern is highly correlated with BECTS, it can also occur in asymptomatic children.",
"     </li>",
"     <li>",
"      A typical history and EEG are sufficient to establish the diagnosis of BECTS. The possibility of symptomatic epilepsy should be evaluated with magnetic resonance imaging when there are atypical features.",
"     </li>",
"     <li>",
"      We suggest NOT routinely using antiepileptic drugs in BECTS (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Antiepileptic drugs with efficacy in partial seizures can reduce the frequency of secondary generalized seizures in BECTS and can be considered in those patients with a high frequency or severity of seizures. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of the treatment of seizures and epileptic syndromes in children\", section on 'Choice of drug'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In most cases, seizures remit before or during adolescence, and neurologic development is normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Panayiotopoulos syndrome describes a benign partial epilepsy associated with interictal occipital spikes that begins in early childhood (mean age five years) with rare seizures that have prominent autonomic features (eg, vomiting, pallor) and are often prolonged. Half of patients have only a single seizure, and prophylactic treatment may not be required. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Panayiotopoulos syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Benign occipital epilepsy of childhood (Gastaut-type) presents at a mean age of nine years with seizures that have prominent visual symptoms including blindness and hallucinations. Seizures usually occur during the daytime and are brief, but can be frequent, indicating antiepileptic drug treatment in most individuals. EEG demonstrates occipital spikes that are activated by eye closure. Seizures often remit prior to adulthood. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Benign occipital epilepsy of childhood'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/1\">",
"      Panayiotopoulos CP. Benign childhood partial epilepsies: benign childhood seizure susceptibility syndromes. J Neurol Neurosurg Psychiatry 1993; 56:2.",
"     </a>",
"    </li>",
"    <li>",
"     Panayiotopoulos CP. Benign childhood focal seizures and related epileptic syndromes. In: A clinical guide to epileptic syndromes and their treatment, 2nd ed, Panayiotopoulos, CP (Ed), Springer, London 2007. p.285.",
"    </li>",
"    <li>",
"     L&uuml;ders H, Lesser RP, Dinner DS, et al. Benign focal epilepsy of childhood. In: Epilepsy: electroclinical syndromes, L&uuml;ders, H, Lesser, RP (Eds), Springer-Verlag, London 1987. p.303.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/4\">",
"      Kramer U, Zelnik N, Lerman-Sagie T, Shahar E. Benign childhood epilepsy with centrotemporal spikes: clinical characteristics and identification of patients at risk for multiple seizures. J Child Neurol 2002; 17:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/5\">",
"      Kramer U, Nevo Y, Neufeld MY, et al. Epidemiology of epilepsy in childhood: a cohort of 440 consecutive patients. Pediatr Neurol 1998; 18:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/6\">",
"      Cavazzuti GB. Epidemiology of different types of epilepsy in school age children of Modena, Italy. Epilepsia 1980; 21:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/7\">",
"      Bouma PA, Bovenkerk AC, Westendorp RG, Brouwer OF. The course of benign partial epilepsy of childhood with centrotemporal spikes: a meta-analysis. Neurology 1997; 48:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/8\">",
"      Vears DF, Tsai MH, Sadleir LG, et al. Clinical genetic studies in benign childhood epilepsy with centrotemporal spikes. Epilepsia 2012; 53:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/9\">",
"      Vadlamudi L, Harvey AS, Connellan MM, et al. Is benign rolandic epilepsy genetically determined? Ann Neurol 2004; 56:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/10\">",
"      Vadlamudi L, Kjeldsen MJ, Corey LA, et al. Analyzing the etiology of benign rolandic epilepsy: a multicenter twin collaboration. Epilepsia 2006; 47:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/11\">",
"      Neubauer BA. The genetics of rolandic epilepsy. Epileptic Disord 2000; 2 Suppl 1:S67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/12\">",
"      Bali B, Kull LL, Strug LJ, et al. Autosomal dominant inheritance of centrotemporal sharp waves in rolandic epilepsy families. Epilepsia 2007; 48:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/13\">",
"      Pruna D, Persico I, Serra D. Lack of association with the 15q14 candidate region for benign epilepsy of childhood with centro-temporal spikes in a Sardinian population. Epilepsia 2000; 41:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/14\">",
"      Neubauer BA, Waldegger S, Heinzinger J, et al. KCNQ2 and KCNQ3 mutations contribute to different idiopathic epilepsy syndromes. Neurology 2008; 71:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/15\">",
"      Gregory DL, Wong PK. Topographical analysis of the centrotemporal discharges in benign rolandic epilepsy of childhood. Epilepsia 1984; 25:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/16\">",
"      Loiseau P, Beaussart M. The seizures of benign childhood epilepsy with Rolandic paroxysmal discharges. Epilepsia 1973; 14:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/17\">",
"      Uematsu S, Lesser R, Fisher RS, et al. Motor and sensory cortex in humans: topography studied with chronic subdural stimulation. Neurosurgery 1992; 31:59.",
"     </a>",
"    </li>",
"    <li>",
"     Penfield W, Jasper H. Epilepsy and the functional anatomy of the brain, Little, Brown and Co, Boston 1954.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/19\">",
"      Lombroso CT. Sylvian seizures and midtemporal spike foci in children. Arch Neurol 1967; 17:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/20\">",
"      Ma CK, Chan KY. Benign childhood epilepsy with centrotemporal spikes: a study of 50 Chinese children. Brain Dev 2003; 25:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/21\">",
"      Gregory DL, Farrell K, Wong PK. Partial status epilepticus in benign childhood epilepsy with centrotemporal spikes: are independent right and left seizures a risk factor? Epilepsia 2002; 43:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/22\">",
"      Cherian A, Baheti NN, Menon RN, et al. Atonic variant of benign childhood epilepsy with centrotemporal spikes (atonic-BECTS): a distinct electro-clinical syndrome. Brain Dev 2012; 34:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/23\">",
"      Baglietto MG, Battaglia FM, Nobili L, et al. Neuropsychological disorders related to interictal epileptic discharges during sleep in benign epilepsy of childhood with centrotemporal or Rolandic spikes. Dev Med Child Neurol 2001; 43:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/24\">",
"      Lindgren S, Kihlgren M, Melin L, et al. Development of cognitive functions in children with rolandic epilepsy. Epilepsy Behav 2004; 5:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/25\">",
"      Northcott E, Connolly AM, Berroya A, et al. The neuropsychological and language profile of children with benign rolandic epilepsy. Epilepsia 2005; 46:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/26\">",
"      Clarke T, Strug LJ, Murphy PL, et al. High risk of reading disability and speech sound disorder in rolandic epilepsy families: case-control study. Epilepsia 2007; 48:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/27\">",
"      Perkins FF Jr, Breier J, McManis MH, et al. Benign rolandic epilepsy -- perhaps not so benign: use of magnetic source imaging as a predictor of outcome. J Child Neurol 2008; 23:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/28\">",
"      Boatman DF, Trescher WH, Smith C, et al. Cortical auditory dysfunction in benign rolandic epilepsy. Epilepsia 2008; 49:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/29\">",
"      Kavros PM, Clarke T, Strug LJ, et al. Attention impairment in rolandic epilepsy: systematic review. Epilepsia 2008; 49:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/30\">",
"      Vago C, Bulgheroni S, Franceschetti S, et al. Memory performance on the California Verbal Learning Test of children with benign childhood epilepsy with centrotemporal spikes. Epilepsy Behav 2008; 13:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/31\">",
"      Lillywhite LM, Saling MM, Harvey AS, et al. Neuropsychological and functional MRI studies provide converging evidence of anterior language dysfunction in BECTS. Epilepsia 2009; 50:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/32\">",
"      Danielsson J, Petermann F. Cognitive deficits in children with benign rolandic epilepsy of childhood or rolandic discharges: a study of children between 4 and 7 years of age with and without seizures compared with healthy controls. Epilepsy Behav 2009; 16:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/33\">",
"      Cerminara C, D'Agati E, Lange KW, et al. Benign childhood epilepsy with centrotemporal spikes and the multicomponent model of attention: a matched control study. Epilepsy Behav 2010; 19:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/34\">",
"      Tovia E, Goldberg-Stern H, Ben Zeev B, et al. The prevalence of atypical presentations and comorbidities of benign childhood epilepsy with centrotemporal spikes. Epilepsia 2011; 52:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/35\">",
"      Smith AB, Kavros PM, Clarke T, et al. A neurocognitive endophenotype associated with rolandic epilepsy. Epilepsia 2012; 53:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/36\">",
"      Tang SS, Clarke T, Owens J, Pal DK. Sleep behavior disturbances in rolandic epilepsy. J Child Neurol 2011; 26:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/37\">",
"      Berroya AM, Bleasel AF, Stevermuer TL, et al. Spike morphology, location, and frequency in benign epilepsy with centrotemporal spikes. J Child Neurol 2005; 20:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/38\">",
"      Blom S, Heijbel J. Benign epilepsy of children with centro-temporal EEG foci. Discharge rate during sleep. Epilepsia 1975; 16:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/39\">",
"      Frost JD Jr, Hrachovy RA, Glaze DG. Spike morphology in childhood focal epilepsy: relationship to syndromic classification. Epilepsia 1992; 33:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/40\">",
"      Camfield P, Camfield C. Epileptic syndromes in childhood: clinical features, outcomes, and treatment. Epilepsia 2002; 43 Suppl 3:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/41\">",
"      Shevell MI, Rosenblatt B, Watters GV, et al. \"Pseudo-BECRS\": intracranial focal lesions suggestive of a primary partial epilepsy syndrome. Pediatr Neurol 1996; 14:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/42\">",
"      Wirrell EC, Camfield PR, Gordon KE, et al. Benign rolandic epilepsy: atypical features are very common. J Child Neurol 1995; 10:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/43\">",
"      Dai AI, Weinstock A. Postictal paresis in children with benign rolandic epilepsy. J Child Neurol 2005; 20:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/44\">",
"      Datta A, Sinclair DB. Benign epilepsy of childhood with rolandic spikes: typical and atypical variants. Pediatr Neurol 2007; 36:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/45\">",
"      Gelisse P, Corda D, Raybaud C, et al. Abnormal neuroimaging in patients with benign epilepsy with centrotemporal spikes. Epilepsia 2003; 44:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/46\">",
"      Peters JM, Camfield CS, Camfield PR. Population study of benign rolandic epilepsy: is treatment needed? Neurology 2001; 57:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/47\">",
"      Loiseau P, Duch&eacute; B, Cordova S, et al. Prognosis of benign childhood epilepsy with centrotemporal spikes: a follow-up study of 168 patients. Epilepsia 1988; 29:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/48\">",
"      Fejerman N, Caraballo R, Tenembaum SN. Atypical evolutions of benign localization-related epilepsies in children: are they predictable? Epilepsia 2000; 41:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/49\">",
"      Monjauze C, Broadbent H, Boyd SG, et al. Language deficits and altered hemispheric lateralization in young people in remission from BECTS. Epilepsia 2011; 52:e79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/50\">",
"      Datta AN, Oser N, Bauder F, et al. Cognitive impairment and cortical reorganization in children with benign epilepsy with centrotemporal spikes. Epilepsia 2013; 54:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/51\">",
"      Bulgheroni S, Franceschetti S, Vago C, et al. Verbal dichotic listening performance and its relationship with EEG features in benign childhood epilepsy with centrotemporal spikes. Epilepsy Res 2008; 79:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/52\">",
"      Lin JJ, Riley JD, Hsu DA, et al. Striatal hypertrophy and its cognitive effects in new-onset benign epilepsy with centrotemporal spikes. Epilepsia 2012; 53:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/53\">",
"      Tzitiridou M, Panou T, Ramantani G, et al. Oxcarbazepine monotherapy in benign childhood epilepsy with centrotemporal spikes: a clinical and cognitive evaluation. Epilepsy Behav 2005; 7:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/54\">",
"      Bello-Espinosa LE, Roberts SL. Levetiracetam for benign epilepsy of childhood with centrotemporal spikes-three cases. Seizure 2003; 12:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/55\">",
"      Gastaut H. A new type of epilepsy: benign partial epilepsy of childhood with occipital spike-waves. Clin Electroencephalogr 1982; 13:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/56\">",
"      Coppola G, Franzoni E, Verrotti A, et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial. Brain Dev 2007; 29:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/57\">",
"      Hughes JR. Benign epilepsy of childhood with centrotemporal spikes (BECTS): to treat or not to treat, that is the question. Epilepsy Behav 2010; 19:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/58\">",
"      Rating D, Wolf C, Bast T. Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Sulthiame Study Group. Epilepsia 2000; 41:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/59\">",
"      Bourgeois BF. Antiepileptic drugs, learning, and behavior in childhood epilepsy. Epilepsia 1998; 39:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/60\">",
"      Corda D, Gelisse P, Genton P, et al. Incidence of drug-induced aggravation in benign epilepsy with centrotemporal spikes. Epilepsia 2001; 42:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/61\">",
"      Catania S, Cross H, de Sousa C, Boyd S. Paradoxic reaction to lamotrigine in a child with benign focal epilepsy of childhood with centrotemporal spikes. Epilepsia 1999; 40:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/62\">",
"      Braathen G, Andersson T, Gylje H, et al. Comparison between one and three years of treatment in uncomplicated childhood epilepsy: a prospective study. I. Outcome in different seizure types. Epilepsia 1996; 37:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/63\">",
"      Taylor I, Berkovic SF, Kivity S, Scheffer IE. Benign occipital epilepsies of childhood: clinical features and genetics. Brain 2008; 131:2287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/64\">",
"      Covanis A. Panayiotopoulos syndrome: a benign childhood autonomic epilepsy frequently imitating encephalitis, syncope, migraine, sleep disorder, or gastroenteritis. Pediatrics 2006; 118:e1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/65\">",
"      Lada C, Skiadas K, Theodorou V, et al. A study of 43 patients with panayiotopoulos syndrome, a common and benign childhood seizure susceptibility. Epilepsia 2003; 44:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/66\">",
"      Koutroumanidis M. Panayiotopoulos syndrome: an important electroclinical example of benign childhood system epilepsy. Epilepsia 2007; 48:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/67\">",
"      Caraballo R, Cers&oacute;simo R, Fejerman N. Panayiotopoulos syndrome: a prospective study of 192 patients. Epilepsia 2007; 48:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/68\">",
"      Panayiotopoulos CP. Benign childhood epilepsy with occipital paroxysms: a 15-year prospective study. Ann Neurol 1989; 26:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/69\">",
"      Du JC, Chien YH, Weng WC, et al. Clinical analysis of childhood occipital lobe epilepsy in 43 Taiwanese patients. Pediatr Neurol 2007; 36:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/70\">",
"      Oguni H, Hayashi K, Funatsuka M, Osawa M. Study on early-onset benign occipital seizure susceptibility syndrome. Pediatr Neurol 2001; 25:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/71\">",
"      Ferrie C, Caraballo R, Covanis A, et al. Panayiotopoulos syndrome: a consensus view. Dev Med Child Neurol 2006; 48:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/72\">",
"      Panayiotopoulos CP. Benign childhood epileptic syndromes with occipital spikes: new classification proposed by the International League Against Epilepsy. J Child Neurol 2000; 15:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/73\">",
"      Michael M, Tsatsou K, Ferrie CD. Panayiotopoulos syndrome: an important childhood autonomic epilepsy to be differentiated from occipital epilepsy and acute non-epileptic disorders. Brain Dev 2010; 32:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/74\">",
"      Specchio N, Trivisano M, Di Ciommo V, et al. Panayiotopoulos syndrome: a clinical, EEG, and neuropsychological study of 93 consecutive patients. Epilepsia 2010; 51:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/75\">",
"      Ferrie CD, Caraballo R, Covanis A, et al. Autonomic status epilepticus in Panayiotopoulos syndrome and other childhood and adult epilepsies: a consensus view. Epilepsia 2007; 48:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/76\">",
"      Koutroumanidis M, Ferrie CD, Valeta T, et al. Syncope-like epileptic seizures in Panayiotopoulos syndrome. Neurology 2012; 79:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/77\">",
"      De Rose P, Perrino F, Lettori D, et al. Visual and visuoperceptual function in children with Panayiotopoulos syndrome. Epilepsia 2010; 51:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/78\">",
"      Specchio N, Trivisano M, Claps D, et al. Documentation of autonomic seizures and autonomic status epilepticus with ictal EEG in Panayiotopoulos syndrome. Epilepsy Behav 2010; 19:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/79\">",
"      Panayiotopoulos CP, Michael M, Sanders S, et al. Benign childhood focal epilepsies: assessment of established and newly recognized syndromes. Brain 2008; 131:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/80\">",
"      Ozkara C, Benbir G, Celik AF. Misdiagnosis due to gastrointestinal symptoms in an adolescent with probable autonomic status epilepticus and Panayiotopoulos syndrome. Epilepsy Behav 2009; 14:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/81\">",
"      Hirano Y, Oguni H, Funatsuka M, et al. Neurobehavioral abnormalities may correlate with increased seizure burden in children with Panayiotopoulos syndrome. Pediatr Neurol 2009; 40:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/82\">",
"      Caraballo RH, Cers&oacute;simo RO, Fejerman N. Childhood occipital epilepsy of Gastaut: a study of 33 patients. Epilepsia 2008; 49:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/83\">",
"      Caraballo RH, Cers&oacute;simo RO, Fejerman N. Late-onset, \"Gastaut type\", childhood occipital epilepsy: an unusual evolution. Epileptic Disord 2005; 7:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/84\">",
"      Kivity S, Ephraim T, Weitz R, Tamir A. Childhood epilepsy with occipital paroxysms: clinical variants in 134 patients. Epilepsia 2000; 41:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/85\">",
"      Tsai ML, Lo HY, Chaou WT. Clinical and electroencephalographic findings in early and late onset benign childhood epilepsy with occipital paroxysms. Brain Dev 2001; 23:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/86\">",
"      Shahar E, Barak S. Favorable outcome of epileptic blindness in children. J Child Neurol 2003; 18:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/87\">",
"      Caraballo R, Koutroumanidis M, Panayiotopoulos CP, Fejerman N. Idiopathic childhood occipital epilepsy of Gastaut: a review and differentiation from migraine and other epilepsies. J Child Neurol 2009; 24:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/88\">",
"      Martinovi�� Z. Clinical correlations of electroencephalographic occipital epileptiform paroxysms in children. Seizure 2001; 10:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/89\">",
"      Verrotti A, Parisi P, Loiacono G, et al. Levetiracetam monotherapy for childhood occipital epilepsy of gastaut. Acta Neurol Scand 2009; 120:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/90\">",
"      Panayiotopoulos CP. Elementary visual hallucinations, blindness, and headache in idiopathic occipital epilepsy: differentiation from migraine. J Neurol Neurosurg Psychiatry 1999; 66:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/91\">",
"      Chahine LM, Mikati MA. Benign pediatric localization-related epilepsies. Part I. Syndromes in infancy. Epileptic Disord 2006; 8:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/921/abstract/92\">",
"      Capovilla G, Vigevano F. Benign idiopathic partial epilepsies in infancy. J Child Neurol 2001; 16:874.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6158 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E9068B15A1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_57_921=[""].join("\n");
var outline_f0_57_921=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BENIGN EPILEPSY WITH CENTROTEMPORAL SPIKES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Electroencephalography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      BENIGN CHILDHOOD EPILEPSY WITH OCCIPITAL SPIKES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Panayiotopoulos syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Clinical symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Electroencephalography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Benign occipital epilepsy of childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      BENIGN PARTIAL EPILEPSIES IN INFANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6158\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6158|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?24/3/24634\" title=\"waveform 1\">",
"      EEG Benign epilepsy with centrotemporal spikes BCECTS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=related_link\">",
"      Epilepsy syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=related_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=related_link\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35783?source=related_link\">",
"      Neonatal epileptic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/54/38754?source=related_link\">",
"      Patient information: Epilepsy in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/26/419?source=related_link\">",
"      Patient information: Seizures in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/5/19540?source=related_link\">",
"      Patient information: Treatment of seizures in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_57_922="Right ventricular myocardial infarction";
var content_f0_57_922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Right ventricular myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/57/922/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/57/922/contributors\">",
"     Thomas Levin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/57/922/contributors\">",
"     James A Goldstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/57/922/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/57/922/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/57/922/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/57/922/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/57/922/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/57/922/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute myocardial infarction (MI) involving only the right ventricle is an uncommon event. More often, right ventricular infarction (RVMI) is associated with acute ST-elevation myocardial infarction of the inferior wall of the left ventricle, and occurs in 30 to 50 percent of such cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RVMI is associated with higher in-hospital morbidity and mortality compared to patients with a similar infarction territory in the left ventricle but that does not involve the right ventricle. Poor outcome is usually related to profound hemodynamic and electrical complications, which occur in approximately 50 percent of affected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/1-9\">",
"     1-9",
"    </a>",
"    ]. However, long-term prognosis is generally good for those who survive the event.",
"   </p>",
"   <p>",
"    This topic will discuss the diagnosis and management of patients with RVMI. The general approach to patients with MI is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7098?source=see_link\">",
"     \"Overview of the non-acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=see_link\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34542532\">",
"    <span class=\"h1\">",
"     BASIC CONCEPTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21351485\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following terms which are used in this topic are defined as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Stroke volume",
"      </strong>",
"      is the amount of blood pumped with each beat. It is influenced by preload, afterload, and contractility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23076?source=see_link&amp;anchor=H2#H2\">",
"       \"Pathophysiology of heart failure: Left ventricular pressure-volume relationships\", section on 'Normal left ventricular pressure-volume relationship'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Preload",
"      </strong>",
"      is the volume of blood within the left or right ventricle at the end if diastole (the filling period). Up to a point, increasing preload leads to a rise in stroke volume. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23076?source=see_link&amp;anchor=H3#H3\">",
"       \"Pathophysiology of heart failure: Left ventricular pressure-volume relationships\", section on 'Preload'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Afterload",
"      </strong>",
"      is the resistance to forward flow from the right or left ventricle (",
"      <a class=\"graphic graphic_figure graphicRef55742 \" href=\"UTD.htm?38/50/39725\">",
"       figure 1",
"      </a>",
"      ). In patients with ventricular dysfunction, increasing afterload leads to a fall in stroke volume. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23076?source=see_link&amp;anchor=H5#H5\">",
"       \"Pathophysiology of heart failure: Left ventricular pressure-volume relationships\", section on 'Afterload'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Contractility",
"      </strong>",
"      is the strength of contraction (at any ventricular size) of the myocardial muscle. Up to a point, increasing contractility increases stroke volume. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23076?source=see_link&amp;anchor=H4#H4\">",
"       \"Pathophysiology of heart failure: Left ventricular pressure-volume relationships\", section on 'Contractility'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiac output",
"      </strong>",
"      is the amount of blood pumped per minute and is the product of the stroke volume and heart rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Right ventricular infarction versus ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term RV &ldquo;infarction&rdquo; is, to an extent, a misnomer, as most cases of acute RV ischemic dysfunction appear to represent predominantly viable myocardium. This is in marked contrast to the effects of ischemia and reperfusion on the left ventricle in which prolonged ischemia often leads to infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The following observations support ischemia, rather than infarction, as the mechanism by which adverse outcomes are precipitated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Right ventricular function improves in the majority of patients with right ventricular infarction, including those who are not reperfused [",
"      <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/7,8,12-14\">",
"       7,8,12-14",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Long-term prognosis'",
"      </a>",
"      below.) There are several factors that make the right ventricle less susceptible to infarction:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Compared to the left ventricle, oxygen demand is significantly lower in the right ventricle because of its much smaller muscle mass and lower afterload [",
"      <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coronary perfusion in the right ventricle occurs in both systole and diastole [",
"      <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is more extensive collateral flow from left to right coronary arteries [",
"      <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The right ventricle may also be protected from infarction to a greater degree than the left ventricle by ischemic preconditioning [",
"      <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=see_link\">",
"       \"Clinical implications of ischemic preconditioning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic right heart failure attributable to RVMI is rare.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Site of the culprit lesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most individuals, the majority of the right ventricle (RV) is supplied by the right coronary artery through right ventricular marginal branches. Thus, the majority of right ventricular infarcts result from occlusion of the right coronary artery proximal to the origin of the major RV branches [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/1-3,5,20,21\">",
"     1-3,5,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in patients with a left dominant system, which occurs in about 15 percent of the general population (or those with a chronically occluded proximal right coronary artery and significant collateral blood flow from either the left anterior descending or circumflex coronary artery), more than 50 percent of the right ventricle can be supplied by the left coronary circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34542612\">",
"    <span class=\"h2\">",
"     Hemodynamic consequences",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemodynamic consequences of RVMI depend on the extent of RV free wall dysfunction, the presence of concomitant right atrial ischemia (resulting from very proximal occlusions) which leads to underfilling of the RV, and the extent of simultaneous left ventricular impairment. Clinically evident hemodynamic manifestations are seen in less than 50 percent of affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/22\">",
"     22",
"    </a>",
"    ]. It should be kept in mind that in patients with RVMI, hemodynamic compromise may be due to RV dysfunction, left ventricular (LV) dysfunction, or a combination of these. In some cases, the relative contribution of the right and left ventricles may be uncertain and hemodynamic monitoring may be required both to understand the pathophysiology and to guide treatment. (See",
"    <a class=\"local\" href=\"#H3300080\">",
"     'Hemodynamic monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Proximal occlusion of the right coronary artery compromises RV free wall perfusion leading to dyskinesis and depressed global RV performance [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/2,6,19,20\">",
"     2,6,19,20",
"    </a>",
"    ]. This leads to a fall in the delivery of blood to the left ventricle and decreased systemic cardiac output despite intact LV systolic performance. RV (and LV) diastolic dysfunction also contributes to hemodynamic compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/23\">",
"     23",
"    </a>",
"    ]. The ischemic RV is stiff and dilated early in diastole, impeding inflow from the right atrium and leading to rapid diastolic pressure elevation. RV dilatation and elevated diastolic pressure shift the interventricular septum toward the volume deprived LV, further impairing left ventricular (LV) compliance and filling. Abrupt RV dilatation within the non-compliant pericardium elevates intrapericardial pressure, the resultant constraint further intensifying septal-mediated diastolic ventricular interactions and thereby impairing both RV and LV compliance and filling.",
"   </p>",
"   <p>",
"    Other factors that may worsen the hemodynamic profile of patients with RVMI include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Right atrial ischemia can impair right atrial function, worsening the hemodynamic changes [",
"      <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/21,24\">",
"       21,24",
"      </a>",
"      ].This occurs when the culprit right coronary artery lesion is proximal to the right atrial branches.",
"     </li>",
"     <li>",
"      Depression of LV function (for example, from prior MI) may exacerbate hemodynamic compromise for any degree of ischemic RV dysfunction. This effect is attributable not only due to loss of LV power, but also due to the fact that under conditions of severely depressed RV free wall contraction, RV performance is dependent on LV-septal contraction, which is generally abnormal with prior LV systolic dysfunction.",
"     </li>",
"     <li>",
"      Tricuspid valve regurgitation, caused by ischemia to the papillary muscle or by dilatation of the tricuspid annulus.",
"     </li>",
"     <li>",
"      Mechanical complications of MI such as ventricular septal rupture [",
"      <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/2,25\">",
"       2,25",
"      </a>",
"      ]. The left-to-right shunting further reduces left ventricular output and exacerbates the right ventricular dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=see_link\">",
"       \"Mechanical complications of acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3299644\">",
"    <span class=\"h2\">",
"     Electrical consequences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradyarrhythmias and tachyarrhythmias occur in patients with RVMI and contribute to the poor short-term outcome in some patients.",
"   </p>",
"   <p>",
"    Bradycardia may be due to sinoatrial or atrioventricular nodal dysfunction due to ischemia, activation of cardioinhibitory reflexes, or both. Patients with acute RVMI are at increased risk for both high-grade AV block and bradycardia-hypotension without AV block compared to those with inferior MI alone [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/2,9,26-28\">",
"     2,9,26-28",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=see_link\">",
"     \"Conduction abnormalities after myocardial infarction\"",
"    </a>",
"    .) The presence of sinus bradycardia (without atrioventricular [AV] block) and hypotension raises the possibility of cardioinhibitory (Bezold-Jarisch) reflexes arising from stimulation of vagal afferents located in the ischemic LV inferoposterior wall as well as the ischemic RV [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ventricular arrhythmias, including tachycardia and fibrillation, complicate up to one-third of cases of RVMI [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/9,30\">",
"     9,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient presenting with an acute MI (particularly ST-elevation MI), the major clinical features of a hemodynamically significant RVMI include hypotension, elevated jugular venous pressure, and clear lung fields and an electrocardiogram with evidence of an acute inferior MI. ST-elevation &gt;1mm in lead V4R has sensitivity and specificity &gt;90 percent for scintigraphic evidence of RV infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/31\">",
"     31",
"    </a>",
"    ], and approximately 80 percent for echocardiographic evidence of RV dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/32\">",
"     32",
"    </a>",
"    ]. The right-sided ST elevation is often transient. &nbsp;",
"   </p>",
"   <p>",
"    The extent to which RVMI impacts the clinical presentation depends on its size and the relative degree of left ventricular dysfunction. A small RVMI may not lead to hypotension or elevated jugular venous pressure. For these smaller RVMI, making the diagnosis is less important (than in patients with larger RVMI), as standard care for (left ventricular) MI will lead to optimal patient care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267508435\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of RVMI are those common to the broad population of patients with MI: chest pain, nausea, vomiting, diaphoresis, dizziness, and anxiety. However, isolated or predominant RVMI does not cause dyspnea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On examination, patients with large RVMI typically present with hypotension (and occasionally shock) and jugular vein distention in the presence of clear lung fields [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/33\">",
"     33",
"    </a>",
"    ]. These physical examination findings in a patient having an MI, although specific, are not sensitive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These findings are in contrast to those found in patients with predominant left ventricular infarction where pulmonary congestion, third or fourth heart sounds, and a new mitral valve murmur may be notable (",
"    <a class=\"graphic graphic_table graphicRef62368 \" href=\"UTD.htm?11/61/12252\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The heart rate in patients with RVMI is generally slower than those with predominant left ventricular MI. Those patients with bradycardia due to vagotonic influences are more likely to manifest other signs of vagal excess, including pallor, diaphoresis, nausea, and vomiting. (See",
"    <a class=\"local\" href=\"#H3299644\">",
"     'Electrical consequences'",
"    </a>",
"    above.) Tachycardia may be present and is often due to sympathetic discharge related to anxiety or as a compensatory mechanism to raise low cardiac output. (See",
"    <a class=\"local\" href=\"#H21351485\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3299104\">",
"    <span class=\"h2\">",
"     Electrocardiographic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;An electrocardiogram (ECG) should be obtained in all patients with symptoms suspicious for myocardial ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link&amp;anchor=H3#H3\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\", section on 'Immediate ED interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any patient with symptoms of an ACS and electrocardiographic evidence of inferior wall ischemia or infarction, as evidenced by abnormalities of the ST segment or T wave in leads II, III, and aVF, should have right-sided leads V4R, V5R, and V6R obtained to assess for a possible right ventricular infarct. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link&amp;anchor=H10#H10\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\", section on 'Inferior and right ventricular MI'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link&amp;anchor=H15#H15\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\", section on 'Inferior MI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ECG in patients with right ventricular infarction may demonstrate &ge;1 mm of doming ST elevation in the right sided precordial leads V4R to V6R (",
"    <a class=\"graphic graphic_waveform graphicRef82739 \" href=\"UTD.htm?42/21/43354\">",
"     waveform 1",
"    </a>",
"    ). Right sided ST elevation, particularly in V4R, is indicative of acute right ventricular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/9,31,34,35\">",
"     9,31,34,35",
"    </a>",
"    ] and correlates closely with occlusion of the proximal right coronary artery [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. In one report of 200 consecutive patients with acute inferior MI, ST elevation in V4R had a sensitivity and specificity for concurrent right ventricular infarction of 88 and 78 percent (respectively), using findings from the results of autopsy, cardiac catheterization, radionuclide imaging, or hemodynamic monitoring as the &ldquo;gold standard&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/9\">",
"     9",
"    </a>",
"    ]. Greater ST elevation in lead III than in lead II has been suggested as a predictor of right ventricular infarction, but this finding has not been confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of RVMI is strongly suspected when hypotension, raised jugular venous pressure (distended neck veins), and clear lung fields are present in a patient whose 12 lead electrocardiogram has findings of an acute inferior wall infarction as well as ST-elevation in lead V4R. As patients with other diagnoses, such as pericarditis with pericardial tamponade, may present with a similar picture, the diagnosis is usually secured when echocardiography shows RV cavity dilatation and impaired RV free wall motion. Additional testing is rarely needed for diagnostic purposes, but may be helpful for assessment of therapy. The most common circumstance in which additional testing may be necessary is a patient for whom diagnoses of RVMI or pulmonary embolism are still reasonable after echocardiography is performed. (See",
"    <a class=\"local\" href=\"#H7508960\">",
"     'Echocardiography'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Other imaging studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7508960\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent echocardiography (often at the bedside), including evaluation for right ventricular infarction, should be performed in patients with an inferior MI and evidence of hemodynamic compromise. In patients without hemodynamic compromise, this test should not delay referral of such patients to the cardiac catheterization laboratory for emergency percutaneous revascularization of the culprit vessel [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/33,39-43\">",
"     33,39-43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11369?source=see_link\">",
"     \"Role of echocardiography in acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Right ventricular size and function and the degree of tricuspid insufficiency are evaluated along with assessment of left-sided structures and function. The major limitation of echocardiography is suboptimal visualization of cardiac structures in some patients.",
"   </p>",
"   <p>",
"    In studies of patients with either clinical or electrocardiographic features of RVMI and in whom the diagnosis of RVMI was confirmed with autopsy, surgery, radionuclide ventriculography, or hemodynamic monitoring, the most reliable echocardiographic signs of hemodynamically important right ventricular infarction were [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Right ventricular cavity dilatation; cases with RA ischemia may have RA dilation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impaired right ventricular free wall motion (hypokinesis, akinesis, or dyskinesis). The extent of right ventricular wall motion abnormality can vary from affecting only a small region adjacent to the inferior septum and left ventricular inferior segment to affecting a large portion of the right ventricular free wall. Patients with RVMI and hemodynamic compromise are likely to have wall motion abnormalities in a high percent of the right ventricle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diastolic reversed septal curvature, systolic paradoxic septal motion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased tricuspid annular plane systolic excursion (TAPSE)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reduced right ventricular ejection fraction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27766?source=see_link&amp;anchor=H6#H6\">",
"       \"Echocardiographic evaluation of the right ventricle\", section on 'Contractility'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Plethora of the inferior vena cava. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31528?source=see_link&amp;anchor=H21#H21\">",
"       \"Echocardiographic evaluation of the atria and appendages\", section on 'Vena cava'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impairment of tissue Doppler measures of right ventricular systolic function [",
"      <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/44,45\">",
"       44,45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The specificity of the findings may be decreased by pre-existent pulmonary disease, such as chronic obstructive lung disease or pulmonary embolism. Pre-existent significant pulmonary artery systolic hypertension (&gt;45 to 50 mmHg) leads to echocardiographic abnormalities of right ventricular structure and function (ie, right ventricular dilatation and tricuspid regurgitation) that mimic some of the findings of RVMI.",
"   </p>",
"   <p>",
"    Echocardiography is also helpful in identifying cardiac tamponade, which can present similarly, as well as the rare complication of acute ventricular septal rupture complicating RVI. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3300080\">",
"    <span class=\"h2\">",
"     Hemodynamic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a minority of patients, due to the limitations of echocardiography, a secure diagnosis of RVMI may not possible. In such patients, placement of a pulmonary artery catheter may provide additional diagnostic information. However, it should be emphasized that an ischemic RV is prone to catheter-induced ventricular arrhythmias and this procedure should be performed with great caution in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link&amp;anchor=H7#H7\">",
"     \"Pulmonary artery catheterization: Indications and complications\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemodynamically significant RV infarcts are associated with elevations in right atrial pressure to &ge;10 mmHg and a ratio of right atrial pressure to pulmonary capillary wedge pressure to &gt;0.8 (normal mean value &lt;0.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/41,46,47\">",
"     41,46,47",
"    </a>",
"    ]. In addition, the cardiac index is decreased. The diastolic filling pressures in the RA, RV, and PCW, as well as the LV, may be elevated and equalized. Kussmaul&rsquo;s sign may be evident in the RA pressure trace (or the jugular venous pulse), reflecting inspiratory augmentation of venous return to a dilated and non-compliant right heart. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link&amp;anchor=H20#H20\">",
"     \"Examination of the jugular venous pulse\", section on 'Kussmaul's sign'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As mentioned above, patients with hemodynamically significant RVMI may also have important left ventricular dysfunction, which may prevent the profile presented here from manifesting.",
"   </p>",
"   <p>",
"    Once placed, a pulmonary artery catheter may be useful to assess the impact of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac magnetic resonance imaging (CMR) is considered the standard imaging technique for detailed evaluation of right ventricular structure and function. Although contrast-enhanced cardiovascular magnetic resonance is more sensitive for the detection of right ventricular involvement than physical examination, electrocardiography, and echocardiography in patients with an inferior MI [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/48\">",
"     48",
"    </a>",
"    ], we do not recommend its use, as it has not been shown to improve patient care in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H36992805#H36992805\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Infarct detection and sizing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnoses most often confused with RVMI include pulmonary embolism (with ST elevation in the right-sided precordial leads caused by &ldquo;strain&rdquo;), pericarditis with pericardial tamponade (with ST elevation in many leads, including right sided leads), and anteroseptal MI (ST elevation in leads V1 and V2 may be seen with an RV injury pattern). As discussed above, all patients with suspected acute RVMI and significant hemodynamic compromise should undergo urgent echo, which will typically distinguish among these diagnoses.",
"   </p>",
"   <p>",
"    Of these, pulmonary embolism (PE) and RVMI are most often confused. Both can present with chest pain and findings of clear lung fields and hypotension (including shock) on examination. The nature of the chest pain (ischemic versus pleuritic) may be helpful in making a distinction. The electrocardiogram is usually sufficient to discriminate between the two: ST elevation in the inferior leads is rarely present in patients with PE. Elevation of serum troponin may be present with either diagnosis.",
"   </p>",
"   <p>",
"    On echocardiography, right ventricular systolic dysfunction may be seen with both diagnoses. Sparing of the right ventricular apex (\"McConnell's sign\") has been suggested to be specific for a large PE in some reports [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/49\">",
"     49",
"    </a>",
"    ], but not others [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/50\">",
"     50",
"    </a>",
"    ]. We do not consider this finding specific for PE. If the diagnosis remains uncertain, additional testing, such as helical CT scanning or",
"    <span class=\"nowrap\">",
"     ventilation/perfusion",
"    </span>",
"    scanning, may be necessary to establish the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, patients with RVMI are treated in a manner similar to those with acute ST-elevation MI. This includes the early use of dual oral antiplatelet (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus a platelet P2Y12 receptor blocker), statin therapy, and an anticoagulant. However, medications to improve chest pain such as opioids, nitrates, and beta blockers should be used with caution due to their potential to negatively impact preload (opioids and nitrates) or heart rate and contractility (beta blockers and calcium channel blockers). (See",
"    <a class=\"local\" href=\"#H105309998\">",
"     'Antiischemic drug therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Optimization of right ventricular preload'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Reperfusion, particularly with primary percutaneous coronary intervention, should be initiated as soon as possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with RVMI, there is a spectrum of the relative contributions of right and left ventricular dysfunction. (See",
"    <a class=\"local\" href=\"#H34542612\">",
"     'Hemodynamic consequences'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3299644\">",
"     'Electrical consequences'",
"    </a>",
"    above.) Thus, the approach to treatment of abnormal hemodynamics may differ according to the relative contributions. Optimal management requires information obtained from a two-dimensional echocardiogram; some patients will need hemodynamic monitoring. (See",
"    <a class=\"local\" href=\"#H7508960\">",
"     'Echocardiography'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3300080\">",
"     'Hemodynamic monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Therapy in patients who are hypotensive due to predominant RVMI is aimed at improving right ventricular output [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/2,33\">",
"     2,33",
"    </a>",
"    ]. This is achieved by optimizing right ventricular preload and afterload. In patients who do not respond to these interventions, inotropic support may be necessary to improve right ventricular contractility. In addition, optimization of right ventricular output may require reversing bradycardia or atrioventricular dyssynchrony with appropriate pacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Optimization of right ventricular preload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous fluid (usually isotonic saline) should be given to patients with evidence of low cardiac output (hypotension, hypoperfusion, and a low or normal jugular venous [JVP] pressure) who do not have pulmonary congestion or evidence of right heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/33\">",
"     33",
"    </a>",
"    ]. This is done to enhance preload and thus improve forward flow out of the right ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/2,21,46\">",
"     2,21,46",
"    </a>",
"    ]. The reported efficacy of this approach is variable, a probable reflection of differences in initial volume status [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most cases, a carefully monitored volume challenge is initiated by infusing aliquots of 200 to 300 mL of normal saline while serially assessing the JVP and blood pressure. An invasive catheter can also be employed, but such instrumentation should not delay emergency revascularization of the infarct-related artery. Once rapid volume infusion results in increases in JVP (or, invasively, the pulmonary capillary wedge pressure) to approximately 15 mmHg without corresponding increases in aortic pressure, further volume expansion is not likely to improve hemodynamics [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nitrates, which are often used to relieve angina, and diuretics, which are given to patients with evidence of pulmonary congestion should be avoided, as they both reduce RV preload. Similarly, opioid drugs may lower preload. An increase in vagal tone caused by insertion of a bladder catheter can acutely decrease preload and lead to cardiogenic shock.",
"   </p>",
"   <p>",
"    While awaiting the potential benefits of volume loading (or if fluids alone are not sufficient), severe hypotension must be stabilized through administration of inotropic therapy and vasopressors. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Inotropic drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Optimization of right ventricular afterload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right ventricular output may be further compromised by abnormally high right ventricular afterload, which can occur for a variety of reasons, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Left ventricular dysfunction with elevation in pulmonary venous pressure",
"     </li>",
"     <li>",
"      Hypoxemia from interstitial pulmonary edema, with pulmonary artery vasoconstriction",
"     </li>",
"     <li>",
"      Alpha-adrenergic agonists causing pulmonary vasoconstriction",
"     </li>",
"     <li>",
"      Mechanical ventilation with positive end-expiratory pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with predominant RV dysfunction, RV afterload reducing therapy is not indicated and may worsen the hemodynamic profile. In patients with RVMI and significant left ventricular dysfunction, the use of an intra-aortic balloon pump and occasionally afterload reducing agents may be effective in unloading the left ventricle and subsequently the right ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link&amp;anchor=H24#H24\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Intraaortic balloon pump'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link&amp;anchor=H17#H17\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Vasopressors and inotropes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105309893\">",
"    <span class=\"h2\">",
"     Optimization of heart rate and AV synchrony",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with RVMI, the indications for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    and temporary pacemakers are similar to the broad population of patients with MI.",
"   </p>",
"   <p>",
"    The ischemic right ventricle has a relatively fixed stroke volume and therefore right ventricular output is dependent upon heart rate and optimal transport of blood from the right atrium to the RV (referred to as atrioventricular [AV] transport). (See",
"    <a class=\"local\" href=\"#H34542612\">",
"     'Hemodynamic consequences'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As a result, bradyarrhythmias can significantly worsen the hemodynamic status.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    may be beneficial to increase heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/52\">",
"     52",
"    </a>",
"    ], but right ventricular or atrioventricular sequential pacing (to provide an atrial contribution and atrioventricular [AV] synchrony) may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/2,33,39,53\">",
"     2,33,39,53",
"    </a>",
"    ]. However, right ventricular ischemia may lead to suboptimal results from pacing of the right ventricle. The use of atropine and the indications for temporary transvenous pacing in patients with acute MI are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=see_link&amp;anchor=H24#H24\">",
"     \"Conduction abnormalities after myocardial infarction\", section on 'Use of atropine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21465?source=see_link&amp;anchor=H18#H18\">",
"     \"Temporary cardiac pacing\", section on 'Temporary pacing in acute myocardial infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of significant bradycardia with hypotension after reperfusion is not uncommon in patients with IMI with RV involvement. Profound bradycardia may be followed by ventricular fibrillation. Some of our authors give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    before PCI if there is evidence of vagotonia as suggested by a heart rate &lt;55 beats per minute, even without hypotension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Inotropic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;When fluid resuscitation is insufficient, hypotension should be rapidly corrected with an inotropic agent that also exerts vasoconstrictor effects. Although many vasopressors have been used since the 1940s, few controlled clinical trials have directly compared these agents or documented improved outcomes due to their use [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/54\">",
"     54",
"    </a>",
"    ]. Thus, the manner in which these agents are commonly used largely reflects expert opinion, animal data, and the use of surrogate end points such as tissue oxygenation as a proxy for decreased morbidity and mortality.",
"   </p>",
"   <p>",
"    Dopamine is the initial agent of choice. The usual starting dose of dopamine is 5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute. The dose is titrated up to 15",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute depending upon the clinical response. Frequent ventricular ectopy and ventricular tachycardia may limit the use of this drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link&amp;anchor=H20#H20\">",
"     \"Use of vasopressors and inotropes\", section on 'Dopamine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    is 5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute. The dose is titrated up to 20",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute depending upon the clinical response. Frequent ventricular ectopy and ventricular tachycardia may limit the use of doses above 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute. In addition, since dobutamine decreases peripheral vascular resistance, higher doses may cause hypotension since the cardiac output cannot increase to match the decrease in systemic vascular resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link&amp;anchor=H21#H21\">",
"     \"Use of vasopressors and inotropes\", section on 'Dobutamine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on clinical experience, we treat RVMI patients with hypotension refractory to dopamine with mechanical support using an intra-aortic balloon pump or direct RV support device. (See",
"    <a class=\"local\" href=\"#H346108181\">",
"     'Mechanical assist devices'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Coronary reperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early reperfusion using either primary percutaneous coronary intervention or fibrinolytic therapy can preserve both right and left ventricular function as well as reduce mortality and morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/7,12,20\">",
"     7,12,20",
"    </a>",
"    ]. The indications for and success with these modalities in patients with RVMI are similar to those in patients with left ventricular MI [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/33,39\">",
"     33,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients in whom reperfusion is achieved typically show a dramatic improvement in the hemodynamic profile within 24 hours and exhibit rapid and complete recovery of RV function. Successfully reperfused patients have dramatically lower incidence of sustained bradyarrhythmias, tachyarrhythmias, and hypotension, which translates into excellent short- and long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346108181\">",
"    <span class=\"h2\">",
"     Mechanical assist devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intra-aortic balloon pump is useful for the management of patients with cardiogenic shock due to left ventricular dysfunction. Although there are little data on its benefits in shock due to RVMI, we have found it helpful in stabilizing aortic pressure and improving systemic perfusion in some patients and thus may be temporizing in refractory hypotension while performing emergency percutaneous revascularization and subsequently awaiting recovery of RV function. (See",
"    <a class=\"local\" href=\"#H34542612\">",
"     'Hemodynamic consequences'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13896?source=see_link\">",
"     \"Intraaortic balloon pump counterpulsation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link&amp;anchor=H24#H24\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Intraaortic balloon pump'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In cases with RV shock refractory to the above interventions, right ventricular assist devices may be life-saving, as the ischemic RV ultimately tends to recover over time [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/55\">",
"     55",
"    </a>",
"    ]. The rationale for their use is that forward flow into the pulmonary artery may be improved [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/56\">",
"     56",
"    </a>",
"    ]. Both surgically implantable and catheter based right ventricular assist devices are available, but have not been widely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105309998\">",
"    <span class=\"h2\">",
"     Antiischemic drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers and calcium channel blockers, which might be considered as tools to improve ischemia (and in particular, angina), can reduce heart rate and contractility and slow AV conduction.",
"   </p>",
"   <p>",
"    These drugs should be avoided in patients with RVMI, and in particular, those who are hemodynamically unstable. They can be tried with careful monitoring in those who are stable and have a clear indication [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105309797\">",
"    <span class=\"h2\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association and from the European Society of Cardiology make specific recommendations for the management of patients with RVMI [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. These recommendations are similar to those made in this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of significant right ventricular involvement in acute MI adversely affects the early outcome. Persistent right ventricular dysfunction adversely affects the late prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Early prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the use of primary percutaneous coronary intervention, meta-analyses found that right ventricular involvement in patients with an acute inferior MI was associated with a worse in-hospital outcome due primarily to persistent hypotension and arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/9,12,20,59-61\">",
"     9,12,20,59-61",
"    </a>",
"    ]. In a meta-analysis of six studies, which included 1198 patients, the presence of right ventricular involvement (compared to no RV involvement) was associated with a higher incidence of short-term death (odds ratio [OR] 3.2, 95% CI 2.4-4.1), cardiogenic shock (OR 3.2, 95% CI 2.4-3.5), sustained ventricular tachyarrhythmias (OR 2.7, 95% CI 2.1-3.5), and advanced atrioventricular block (OR 3.4, 95% CI 2.7-4.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/60\">",
"     60",
"    </a>",
"    ]. The increase in mortality appeared to be related to the presence of right ventricular involvement and not to infarct size.",
"   </p>",
"   <p>",
"    Among patients who are diagnosed with RVMI and cardiogenic shock, in-hospital and 30-day mortality have been reported to be 53 and 23 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Long-term prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients with RVMI has dramatically improved with the advent of routinely applied emergency percutaneous revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/12\">",
"     12",
"    </a>",
"    ]. The right ventricle typically recovers much of its function [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/7,8,13,16,46\">",
"     7,8,13,16,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In those who survive RVMI, the long-term prognosis is primarily determined by the extent of left ventricular involvement. This is particularly true in patients with anterior MIs in whom the right ventricle accounts for a much smaller proportion of total infarct size than inferior MIs (7 versus 28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/1\">",
"     1",
"    </a>",
"    ]. Nearly complete recovery of RV function has been shown to occur in 62 to 82 percent of patients within the first few months [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Chronic right heart failure attributable only to right ventricular infarction is rare. Even in those without successful reperfusion, if they survive, RV function returns to near normal at rest and with exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over the long term, a persistent reduction in right ventricular function appears to be associated with a worse long-term prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/8\">",
"     8",
"    </a>",
"    ]. This was illustrated in a study of 147 patients more than 30 days after MI (mean age of infarct 6.7 years) in whom the right ventricular ejection fraction (RVEF) was assessed with contrast enhanced cardiovascular magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?0/57/922/abstract/64\">",
"     64",
"    </a>",
"    ]. During a mean follow-up of 17 months, patients with an RVEF &lt;40 percent had a significantly higher mortality compared to those with an RVEF &gt;40 percent (adjusted hazard ratio 2.9).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H945409504\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Right ventricular myocardial infarction (RVMI) commonly accompanies acute infarction of the inferior wall of the left ventricle, occurring in more than one-third of such cases. The majority of right ventricular infarcts result from occlusion of the proximal right coronary artery. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of RVMI can be strongly suspected when hypotension, raised jugular venous pressure (distended neck veins), and clear lung fields are present in a patient whose 12-lead electrocardiogram has findings of an inferior wall infarction as well as ST-elevation in lead V4R.",
"      <br/>",
"      <br/>",
"      As patients with other diagnoses, such as pericarditis with pericardial tamponade or pulmonary embolism, may present with a similar picture, the diagnosis is usually secured when echocardiography shows RV cavity dilatation and impaired RV free wall motion. For those uncommon patients in whom either RVMI or pulmonary embolism remains a diagnostic possibility after echocardiography, additional testing, such as helical CT scanning or",
"      <span class=\"nowrap\">",
"       ventilation/perfusion",
"      </span>",
"      scanning, may be necessary to establish the diagnosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, patients with RVMI are treated in a manner similar to those with acute ST-elevation MI. This includes the early use of dual oral antiplatelet (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      plus a platelet P2Y12 receptor blocker) and statin therapy as well as anticoagulant. However, drugs that lower preload (eg, nitrates or diuretics), slow heart rate (eg, beta blockers), or decrease contractility (eg, calcium channel blockers) need to be used with caution. Reperfusion, particularly with primary percutaneous coronary intervention, should be initiated as soon as possible. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with RVMI:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with evidence of low cardiac output, clear lung fields, and normal or low jugular venous pressure, small boluses of normal saline should be administered. Medications that decrease preload, such as nitrates or opioids, should be avoided. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Optimization of right ventricular preload'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with persistent hypotension after an attempt to optimize RV preload with normal saline boluses, we suggest adding dopamine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The usual starting dose is 5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per minute. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Inotropic drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with predominant RVMI do not benefit from afterload reducing therapy with either and intra-aortic balloon pump (IABP) or vasodilating agents. However, some patients have increased RV afterload due to left ventricular dysfunction and their hemodynamic profile is determined by biventricular dysfunction. In this setting, the use of an intra-aortic balloon pump or, in uncommon cases vasodilating agents, may improve the hemodynamic profile. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Optimization of right ventricular afterload'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As bradycardia and atrioventricular dyssynchrony can rapidly worsen the hemodynamic status of patients with a right ventricular MI, attempts to correct these electrical abnormalities should be instituted early. The indications for the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      and temporary transvenous pacing are similar to those for the broad population of patients with MI. (See",
"      <a class=\"local\" href=\"#H105309893\">",
"       'Optimization of heart rate and AV synchrony'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/1\">",
"      Andersen HR, Falk E, Nielsen D. Right ventricular infarction: frequency, size and topography in coronary heart disease: a prospective study comprising 107 consecutive autopsies from a coronary care unit. J Am Coll Cardiol 1987; 10:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/2\">",
"      Goldstein JA. Pathophysiology and management of right heart ischemia. J Am Coll Cardiol 2002; 40:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/3\">",
"      Isner JM, Roberts WC. Right ventricular infarction complicating left ventricular infarction secondary to coronary heart disease. Frequency, location, associated findings and significance from analysis of 236 necropsy patients with acute or healed myocardial infarction. Am J Cardiol 1978; 42:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/4\">",
"      Isner JM. Right ventricular myocardial infarction. JAMA 1988; 259:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/5\">",
"      Cabin HS, Clubb KS, Wackers FJ, Zaret BL. Right ventricular myocardial infarction with anterior wall left ventricular infarction: an autopsy study. Am Heart J 1987; 113:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/6\">",
"      Kinch JW, Ryan TJ. Right ventricular infarction. N Engl J Med 1994; 330:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/7\">",
"      Berger PB, Ruocco NA Jr, Ryan TJ, et al. Frequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the thrombolysis in myocardial infarction [TIMI] II trial). The TIMI Research Group. Am J Cardiol 1993; 71:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/8\">",
"      Sakata K, Yoshino H, Kurihara H, et al. Prognostic significance of persistent right ventricular dysfunction as assessed by radionuclide angiocardiography in patients with inferior wall acute myocardial infarction. Am J Cardiol 2000; 85:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/9\">",
"      Zehender M, Kasper W, Kauder E, et al. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med 1993; 328:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/10\">",
"      Bush LR, Buja LM, Samowitz W, et al. Recovery of left ventricular segmental function after long-term reperfusion following temporary coronary occlusion in conscious dogs. Comparison of 2- and 4-hour occlusions. Circ Res 1983; 53:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/11\">",
"      O'Neill W, Timmis GC, Bourdillon PD, et al. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl J Med 1986; 314:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/12\">",
"      Bowers TR, O'Neill WW, Grines C, et al. Effect of reperfusion on biventricular function and survival after right ventricular infarction. N Engl J Med 1998; 338:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/13\">",
"      Dell'Italia LJ, Lembo NJ, Starling MR, et al. Hemodynamically important right ventricular infarction: follow-up evaluation of right ventricular systolic function at rest and during exercise with radionuclide ventriculography and respiratory gas exchange. Circulation 1987; 75:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/14\">",
"      Lim ST, Marcovitz P, Pica M, et al. Right ventricular performance at rest and during stress with chronic proximal occlusion of the right coronary artery. Am J Cardiol 2003; 92:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/15\">",
"      Kusachi S, Nishiyama O, Yasuhara K, et al. Right and left ventricular oxygen metabolism in open-chest dogs. Am J Physiol 1982; 243:H761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/16\">",
"      Lee FA. Hemodynamics of the right ventricle in normal and disease states. Cardiol Clin 1992; 10:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/17\">",
"      Hess DS, Bache RJ. Transmural right ventricular myocardial blood flow during systole in the awake dog. Circ Res 1979; 45:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/18\">",
"      Haupt HM, Hutchins GM, Moore GW. Right ventricular infarction: role of the moderator band artery in determining infarct size. Circulation 1983; 67:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/19\">",
"      Shiraki H, Yoshikawa T, Anzai T, et al. Association between preinfarction angina and a lower risk of right ventricular infarction. N Engl J Med 1998; 338:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/20\">",
"      Zeymer U, Neuhaus KL, Wegscheider K, et al. Effects of thrombolytic therapy in acute inferior myocardial infarction with or without right ventricular involvement. HIT-4 Trial Group. Hirudin for Improvement of Thrombolysis. J Am Coll Cardiol 1998; 32:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/21\">",
"      Goldstein JA, Barzilai B, Rosamond TL, et al. Determinants of hemodynamic compromise with severe right ventricular infarction. Circulation 1990; 82:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/22\">",
"      Kakouros N, Cokkinos DV. Right ventricular myocardial infarction: pathophysiology, diagnosis, and management. Postgrad Med J 2010; 86:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/23\">",
"      Bowers TR, O'Neill WW, Pica M, Goldstein JA. Patterns of coronary compromise resulting in acute right ventricular ischemic dysfunction. Circulation 2002; 106:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/24\">",
"      Goldstein JA, Tweddell JS, Barzilai B, et al. Right atrial ischemia exacerbates hemodynamic compromise associated with experimental right ventricular dysfunction. J Am Coll Cardiol 1991; 18:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/25\">",
"      Moore CA, Nygaard TW, Kaiser DL, et al. Postinfarction ventricular septal rupture: the importance of location of infarction and right ventricular function in determining survival. Circulation 1986; 74:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/26\">",
"      Braat SH, de Zwaan C, Brugada P, et al. Right ventricular involvement with acute inferior wall myocardial infarction identifies high risk of developing atrioventricular nodal conduction disturbances. Am Heart J 1984; 107:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/27\">",
"      Strasberg B, Pinchas A, Arditti A, et al. Left and right ventricular function in inferior acute myocardial infarction and significance of advanced atrioventricular block. Am J Cardiol 1984; 54:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/28\">",
"      Mavri�� Z, Zaputovi�� L, Matana A, et al. Prognostic significance of complete atrioventricular block in patients with acute inferior myocardial infarction with and without right ventricular involvement. Am Heart J 1990; 119:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/29\">",
"      Goldstein JA, Lee DT, Pica MC, et al. Patterns of coronary compromise leading to bradyarrhythmias and hypotension in inferior myocardial infarction. Coron Artery Dis 2005; 16:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/30\">",
"      Ricci JM, Dukkipati SR, Pica MC, et al. Malignant ventricular arrhythmias in patients with acute right ventricular infarction undergoing mechanical reperfusion. Am J Cardiol 2009; 104:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/31\">",
"      Braat SH, Brugada P, de Zwaan C, et al. Value of electrocardiogram in diagnosing right ventricular involvement in patients with an acute inferior wall myocardial infarction. Br Heart J 1983; 49:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/32\">",
"      Candell-Riera J, Figueras J, Valle V, et al. Right ventricular infarction: relationships between ST segment elevation in V4R and hemodynamic, scintigraphic, and echocardiographic findings in patients with acute inferior myocardial infarction. Am Heart J 1981; 101:281.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/34\">",
"      Robalino BD, Whitlow PL, Underwood DA, Salcedo EE. Electrocardiographic manifestations of right ventricular infarction. Am Heart J 1989; 118:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/35\">",
"      Braat SH, Brugada P, De Zwaan C, et al. Right and left ventricular ejection fraction in acute inferior wall infarction with or without ST segment elevation in lead V4R. J Am Coll Cardiol 1984; 4:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/36\">",
"      Braat SH, Gorgels AP, B&auml;r FW, Wellens HJ. Value of the ST-T segment in lead V4R in inferior wall acute myocardial infarction to predict the site of coronary arterial occlusion. Am J Cardiol 1988; 62:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/37\">",
"      Wellens HJ. The value of the right precordial leads of the electrocardiogram. N Engl J Med 1999; 340:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/38\">",
"      Saw J, Davies C, Fung A, et al. Value of ST elevation in lead III greater than lead II in inferior wall acute myocardial infarction for predicting in-hospital mortality and diagnosing right ventricular infarction. Am J Cardiol 2001; 87:448.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/40\">",
"      Kahn JK, Bernstein M, Bengtson JR. Isolated right ventricular myocardial infarction. Ann Intern Med 1993; 118:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/41\">",
"      Goldberger JJ, Himelman RB, Wolfe CL, Schiller NB. Right ventricular infarction: recognition and assessment of its hemodynamic significance by two-dimensional echocardiography. J Am Soc Echocardiogr 1991; 4:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/42\">",
"      D'Arcy B, Nanda NC. Two-dimensional echocardiographic features of right ventricular infarction. Circulation 1982; 65:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/43\">",
"      Jugdutt BI. Right Ventricular Infarction: Contribution of Echocardiography to Diagnosis and Management. Echocardiography 1999; 16:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/44\">",
"      Dokainish H, Abbey H, Gin K, et al. Usefulness of tissue Doppler imaging in the diagnosis and prognosis of acute right ventricular infarction with inferior wall acute left ventricular infarction. Am J Cardiol 2005; 95:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/45\">",
"      Kakouros N, Kakouros S, Lekakis J, et al. Tissue Doppler imaging of the tricuspid annulus and myocardial performance index in the evaluation of right ventricular involvement in the acute and late phase of a first inferior myocardial infarction. Echocardiography 2011; 28:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/46\">",
"      Dell'Italia LJ, Starling MR, Crawford MH, et al. Right ventricular infarction: identification by hemodynamic measurements before and after volume loading and correlation with noninvasive techniques. J Am Coll Cardiol 1984; 4:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/47\">",
"      Cohn JN, Guiha NH, Broder MI, Limas CJ. Right ventricular infarction. Clinical and hemodynamic features. Am J Cardiol 1974; 33:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/48\">",
"      Kumar A, Abdel-Aty H, Kriedemann I, et al. Contrast-enhanced cardiovascular magnetic resonance imaging of right ventricular infarction. J Am Coll Cardiol 2006; 48:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/49\">",
"      McConnell MV, Solomon SD, Rayan ME, et al. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol 1996; 78:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/50\">",
"      Casazza F, Bongarzoni A, Capozi A, Agostoni O. Regional right ventricular dysfunction in acute pulmonary embolism and right ventricular infarction. Eur J Echocardiogr 2005; 6:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/51\">",
"      Ferrario M, Poli A, Previtali M, et al. Hemodynamics of volume loading compared with dobutamine in severe right ventricular infarction. Am J Cardiol 1994; 74:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/52\">",
"      Goodfellow J, Walker PR. Reversal of atropine-resistant atrioventricular block with intravenous aminophylline in the early phase of inferior wall acute myocardial infarction following treatment with streptokinase. Eur Heart J 1995; 16:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/53\">",
"      Topol EJ, Goldschlager N, Ports TA, et al. Hemodynamic benefit of atrial pacing in right ventricular myocardial infarction. Ann Intern Med 1982; 96:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/54\">",
"      M&uuml;llner M, Urbanek B, Havel C, et al. Vasopressors for shock. Cochrane Database Syst Rev 2004; :CD003709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/55\">",
"      Weiss S, Jolly N, Shah AP. Multivessel intervention and placement of a percutaneous right ventricular assist device in a patient with acute myocardial infarction complicated by cardiac arrest. J Invasive Cardiol 2011; 23:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/56\">",
"      Arrieta-Garcia C, Klein LW. Right ventricular assist devices in right ventricular infarction: do they augment right ventricular function sufficiently to improve prognosis? J Invasive Cardiol 2011; 23:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/57\">",
"      Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29:2909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/58\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/59\">",
"      Bueno H, L&oacute;pez-Palop R, Bermejo J, et al. In-hospital outcome of elderly patients with acute inferior myocardial infarction and right ventricular involvement. Circulation 1997; 96:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/60\">",
"      Mehta SR, Eikelboom JW, Natarajan MK, et al. Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction. J Am Coll Cardiol 2001; 37:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/61\">",
"      Gumina RJ, Wright RS, Kopecky SL, et al. Strong predictive value of TIMI risk score analysis for in-hospital and long-term survival of patients with right ventricular infarction. Eur Heart J 2002; 23:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/62\">",
"      Jacobs AK, Leopold JA, Bates E, et al. Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. J Am Coll Cardiol 2003; 41:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/63\">",
"      Brodie BR, Stuckey TD, Hansen C, et al. Comparison of late survival in patients with cardiogenic shock due to right ventricular infarction versus left ventricular pump failure following primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol 2007; 99:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/57/922/abstract/64\">",
"      Larose E, Ganz P, Reynolds HG, et al. Right ventricular dysfunction assessed by cardiovascular magnetic resonance imaging predicts poor prognosis late after myocardial infarction. J Am Coll Cardiol 2007; 49:855.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 75 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-794AB5B1AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_57_922=[""].join("\n");
var outline_f0_57_922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H945409504\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34542532\">",
"      BASIC CONCEPTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21351485\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Right ventricular infarction versus ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Site of the culprit lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34542612\">",
"      Hemodynamic consequences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3299644\">",
"      Electrical consequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H267508435\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3299104\">",
"      Electrocardiographic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7508960\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3300080\">",
"      Hemodynamic monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Optimization of right ventricular preload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Optimization of right ventricular afterload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105309893\">",
"      Optimization of heart rate and AV synchrony",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Inotropic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Coronary reperfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H346108181\">",
"      Mechanical assist devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105309998\">",
"      Antiischemic drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105309797\">",
"      Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Early prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Long-term prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H945409504\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/75\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/75|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/50/39725\" title=\"figure 1\">",
"      Afterload and cardiac output",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/75|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/61/12252\" title=\"table 1\">",
"      Left vs right ventricular MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/75|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/21/43354\" title=\"waveform 1\">",
"      ECG acute inferior and right ventricular myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=related_link\">",
"      Clinical implications of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=related_link\">",
"      Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=related_link\">",
"      Conduction abnormalities after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31528?source=related_link\">",
"      Echocardiographic evaluation of the atria and appendages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27766?source=related_link\">",
"      Echocardiographic evaluation of the right ventricle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13896?source=related_link\">",
"      Intraaortic balloon pump counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7098?source=related_link\">",
"      Overview of the non-acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23076?source=related_link\">",
"      Pathophysiology of heart failure: Left ventricular pressure-volume relationships",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11369?source=related_link\">",
"      Role of echocardiography in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21465?source=related_link\">",
"      Temporary cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_57_923="Non-organic signs Waddell";
var content_f0_57_923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Waddell's non-organic signs (physical examination findings associated with persistent low back pain)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Overreaction during physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Superficial or widespread tenderness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inconsistent supine and seated (distracted) straight leg raise test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unexplainable neurologic deficits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain on simulated axial load (top of head pressure)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_57_923=[""].join("\n");
var outline_f0_57_923=null;
var title_f0_57_924="Management of women with previous PTD or 2nd trimester loss";
var content_f0_57_924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of women with previous preterm delivery or second trimester loss",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Patient population",
"       </td>",
"       <td class=\"subtitle1\">",
"        Interventions to be considered",
"       </td>",
"       <td class=\"subtitle1\">",
"        Options in next pregnancy if history-indicated cerclage was not successful (ie, preterm birth &lt;33 weeks)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women with:",
"        <br/>",
"        <ul>",
"         <li>",
"          &ge;2 consecutive prior second trimester losses*,",
"          <strong>",
"           or",
"          </strong>",
"         </li>",
"         <li>",
"          &ge;3 early (&lt;34 weeks) preterm births",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         Transvaginal cerclage at 12 to 14 weeks, and",
"        </p>",
"        <p>",
"         17-alpha-hydroxyprogesterone caproate 250 mg IM weekly from 16 to 36 weeks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Transabdominal cerclage",
"        </p>",
"        <p>",
"         17-alpha-hydroxyprogesterone caproate 250 mg IM weekly from 16 to 36 weeks",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Women with:",
"        <br/>",
"        <ul>",
"         <li>",
"          One prior second trimester loss*,",
"          <strong>",
"           or",
"          </strong>",
"         </li>",
"         <li>",
"          One or two preterm births &lt;37 weeks",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         17-alpha-hydroxyprogesterone caproate 250 mg IM weekly from 16 to 36 weeks",
"        </p>",
"        <p>",
"         Serial measurement of cervical length beginning at 14 to 16 weeks and ending at 24 weeks (see table entitled \"Protocol for cervical length screening\")",
"        </p>",
"        <p>",
"         If cervical length &lt;25 mm before 24 weeks, place transvaginal cerclage",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Usually a spontaneous pregnancy loss between 16 and 27 6/7ths weeks of gestation.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Iams JD, Berghella V. Care for women with prior preterm birth. Am J Obstet Gynecol 2010; 203:89.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_57_924=[""].join("\n");
var outline_f0_57_924=null;
var title_f0_57_925="One-day rush with subsequent schedule";
var content_f0_57_925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F74051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F74051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    One-day rush schedule for venom immunotherapy with subsequent build-up to full maintenance",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Time",
"       </td>",
"       <td class=\"subtitle1\">",
"        Volume, mL",
"       </td>",
"       <td class=\"subtitle1\">",
"        Concentration, micrograms/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        30",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        45",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        60",
"       </td>",
"       <td>",
"        0.08",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        75",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        90",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        105",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        120",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        135",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        11",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Monthly",
"        </strong>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The accelerated portion of the protocol is shown at the top, followed by subsequent weekly visits to reach full maintenance, as recommended by the manufacturer of the venom extract being administered. In this example, the subsequent build-up follows the schedule recommended by Hollister-Stier (Spokane, Washington). This is the protocol used by the authors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Accelerated initial protocol from: Bernstein JA, Kagen SL, Bernstein DI, Bernstein IL. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy 1994; 73:423. If ALK-Abello (Round Rock, Texas) extracts were used, the schedule in the package insert could be followed to complete the build-up phase.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_57_925=[""].join("\n");
var outline_f0_57_925=null;
var title_f0_57_926="MBG and HbA1c";
var content_f0_57_926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F62980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F62980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Relation between mean blood glucose concentrations and glycated hemoglobin (A1C) values",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 272px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparison of quarterly mean blood glucose concentrations with quarterly HbA1c values. The dashed lines represent 95 percent confidence intervals for individual values. The observed relationship applies only to the Diabetes Control and Complications Trial assay or to assays which have been standardized to it. To convert blood glucose values to mmol/L, multiply by 0.056.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The Diabetes Control and Complications Trial Research Group, Diabetes Care 1987; 10:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_57_926=[""].join("\n");
var outline_f0_57_926=null;
var title_f0_57_927="Molecular basis of LQTS";
var content_f0_57_927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Molecular basis for the long QT syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 327px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ion channels contributing to the cardiac action potential and the impact of genetic mutations.",
"    <div class=\"footnotes\">",
"     +: gain-of-function mutation; &minus;: dominant negative or loss-of-function mutation; LQT: long-QT syndrome; Ito: transient outward current; INa: inward sodium current; ICa: inward calcium current; IKr: rapid component of delayed rectifier current; IKs: slow component of delayed rectifier current; IK1: inward rectifier current; SQT: short-QT syndrome.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Topol EJ, Califf RM, et al. Textbook of Cardiovascular Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_57_927=[""].join("\n");
var outline_f0_57_927=null;
